Page last updated: 2024-11-04

sorbitol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

D-glucitol : The D-enantiomer of glucitol (also known as D-sorbitol). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID453
CHEMBL ID16105
CHEBI ID125392
SCHEMBL ID7559219
SCHEMBL ID764
MeSH IDM0020169
PubMed CID5780
CHEMBL ID1682
CHEBI ID17924
CHEBI ID30911
SCHEMBL ID763
MeSH IDM0020169

Synonyms (300)

Synonym
LS-13225
dl-mannitol
nsc127939
nsc-127939
nsc1944 ,
wln: q1yqyqyqyq1q
syn m.d.
NSC25944 ,
component of probilagol
sorbitol, (d)
sorbit
d-1,3,4,5,6-hexanehexol
nsc-227898
nsc227898
c6h14o6
1,2,3,4,5,6-hexanehexol
hexitol
nsc9256 ,
mannitol, (d)
nsc-9256
mannitol (van8c
nsc407017
wln: q1yqyq 2 -bbaa -d
1,3,4,5,6-hexanehexol
d(-)-mannitol
NCGC00159410-05
NCIOPEN2_007793
D-9500
sorbilax
CHEBI:125392
1AC83243-270A-43FC-AD8D-8C56B1631B19
CHEMBL16105
FT-0693950
FT-0695031
hexane-1,2,3,4,5,6-hexol
STL139313
NCGC00159410-06
NCGC00159410-07
SCHEMBL7559219
AKOS005716939
FT-0627951
FT-0625616
FT-0625628
FT-0627851
FT-0625620
FT-0625542
FT-0628167
hexane-1,2,3,4,5,6-hexaol
d-glucitol-2-13c
HMS3373E11
BRD-A35258977-001-01-7
sorbitol, liniment 60%, mannitol, liniment, d-mannitol, d-sorbitol, dulcitol
smr001550234
MLS006011893
SCHEMBL764
sorbit dp
cystosol
sorbitur
probilagol (salt/mix)
karion, instant
liponic 70-nc
resulax
sorbit d
Q-201051
Q-201336
287112-34-9
fibrinogen fraction 1(from bovine plasma)
Q27215890
HMS3651B03
HMS3656I13
dulcitol diformal
FT-0771376
d-[2-13c]mannitol
FT-0626424
d,l-talitol
d,l-mannitol
d,l-iditol
d,l-sorbitol
115918-59-7
EN300-138618
SY012893
d-[ul-13c6]glucitol
a hexitol
sorbitol;d-glucitol
D86697
SB45133
SB46997
SB44873
SB44866
SB84234
CS-0452692
xylitol ep impurity c
AC-13186
glucitol, d-
e420
CHEBI:17924 ,
glc-ol
d-sorbit
e 420
(2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol
g-ol
e-420
(-)-sorbitol
sorbex r
sorbex rp
cholaxine
sorbilande
sorbex m
sionite
sorbostyl
sorbite
neosorb
siosan
d-sorbol
gulitol
esasorb
sorbex x
nivitin
sionit
sorbo
sionon
sorbicolan
sorbex s
sorvilande
glucitol
nsc-25944
sorbol
diakarmon
d-(-)-sorbitol
sorbitol 3.3% in plastic container
sorbitol 3% in plastic container
einecs 200-061-5
D00096
d-sorbitol (jp17)
sorbitol (nf)
sorbitol 3% in plastic container (tn)
probilagol
MLS001333210
MLS001333209
smr000112219
karion (carbohydrate)
sorbitol f
hsdb 801
neosorb 20/60dc
sorbitol fp
neosorb p 60
sionit k
fema no. 3029
ai3-19424
multitol
glucarine
neosorb 70/02
d-sorbite
ccris 1898
d-1,2,3,4,5,6-hexanehexol
nsc 25944
karion instant
foodol d 70
neosorb p 20/60
neosorb 70/70
d-sorbitol
iso-sorbide
l-gulitol
SORBITOL ,
C00794
(2s,3r,4r,5r)-hexane-1,2,3,4,5,6-hexol
d-glucitol
50-70-4
d-sorbitol, for electrophoresis
d-sorbitol, analytical standard
d-sorbitol, for molecular biology, >=98%
d-sorbitol, bioxtra, >=98%
d-sorbitol, >=98%, fcc, fg
d-sorbitol, bioreagent, cell culture tested, plant cell culture tested
d-sorbitol, plant cell culture tested
d-sorbitol, >=98%
DB01638
NCGC00164353-01
solbitol
dtxsid5023588 ,
medevac
d-sorbitol, bioultra, >=99.5% (hplc)
HMS2094K21
75DE42C3-7C3B-4802-95E0-463F02268BDC
BMSE000115
S0065
ins-420(i)
neosorb p 60w
CHEMBL1682
e-420(i)
sorbitol (e420)
isomalt impurity, sorbitol-
7b5697n
ins no.420(i)
NCGC00164353-02
BMSE000803
5-(4-methoxyphenyl)-1,3-oxazole-4-carboxylicacid
NCGC00257447-01
cas-50-70-4
dtxcid903588
tox21_303388
tox21_201937
NCGC00259486-01
nsc-759608
pharmakon1600-01300028
nsc759608
BMSE001007
HMS2270A18
A15606
(2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexaol
sorbitol [usp:nf]
unii-506t60a25r
506t60a25r ,
sorbogem
NCGC00164353-03
isomalt impurity c [ep impurity]
d-sorbitol [jan]
sorbitol [usp]
lactitol monohydrate impurity e [ep impurity]
sorbitol [ep monograph]
sorbitol [vandf]
sorbitol [ii]
sorbitol [hsdb]
sorbitol component of sorbitol-mannitol
isomalt impurity, sorbitol- [usp impurity]
sorbitol [who-dd]
sorbitol [fcc]
maltitol impurity a [ep impurity]
sorbitol [inci]
sorbitol [usp-rs]
sorbitol [mart.]
sorbitol [mi]
d-sorbitol [fhfi]
sorbitol [orange book]
sorbitol-mannitol component sorbitol
EPITOPE ID:114708
AKOS015899604
S2393
HY-B0400
SCHEMBL763
26566-34-7
neosorb p60
FBPFZTCFMRRESA-JGWLITMVSA-N
wurcs=2.0/1,1,0/[h2122h]/1/
AB00919085_06
mfcd00004708
CCG-229392
d-sorbitol, liquid, tested according to ph.eur.
d-sorbitol, crystallized, >=99.0% (hplc)
d-sorbitol, 99%
d-sorbitol, saj special grade, >=99.0%
d-sorbitol, saj first grade, >=97.0%
sorbitol, united states pharmacopeia (usp) reference standard
d-sorbitol, nf/fcc grade
sorbitol, pharmaceutical secondary standard; certified reference material
d-sorbitol, for synthesis, 99%
sorbitol, european pharmacopoeia (ep) reference standard
d-sorbitol, vetec(tm) reagent grade, 97%
SBI-0206688.P002
sorbit dp 50
sorbit w-powder 50
sorbitol s
sorbit w-powder
sorbit l 70
sorbit d-powder
sorbit wp
kyowa powder 50m
sorbit d 70
sorbit w 70
sorbitol fk
sorbit kyowa powder 50m
sorbogem 712
sorbit s
sorbit t 70
SW220289-1
d-sorbitol; d-glucitol
E70384
sorbitol (glucitol)
Q245280
CS-13177
d-sorbit 1000 microg/ml in methanol
EN300-7832133
sorbitab
sorbitol (ep monograph)
lactitol monohydrate impurity e (ep impurity)
sorbitolum
maltitol impurity a (ep impurity)
sorbitol (ii)
sorbitol instant
sorbitol (usp)
sorbitol (usp-rs)
rel-(2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol
liponic 76-nc
meritol
isomalt impurity c (ep impurity)
chebi:30911
c*pharmsorbidex
isomalt impurity, sorbitol-(usp impurity)
sorbitol (mart.)
sorbitol (usp:nf)

Research Excerpts

Toxicity

The influence of the free radical scavenger 2,4-tetra-O-methyl-furfurylidene-sorbitol (MSF) on the carrageenan-induced hind-paw inflammation in rats is evaluated. The anti-inflammatory and toxic activities of indomethacin is evaluated in comparison with thiola, thioctic acid, silymarin, reduced glutathione and propylgallate.

ExcerptReferenceRelevance
" With respect to sorbitol and xylitol, lactic acidosis was not considered a serious side effect until now."( Possible side effects of glucose, fructose, sorbitol and xylitol in man.
Förster, H, 1976
)
0.26
"The present paper deals with the toxic effect of a mycotoxin of the group of epidithio-dioxopiperazines: cyclo-sarcosyl-sarcosin-epitetrasulfide, particularly upon the liver of guinea-pigs and rats."( [Toxicology of epidithio-dioxopiperazines. 1. Studies on toxicity of cyclosarcosylsarcosineepitetrasulfide in guinea pigs and rats].
Oehlert, W; Schmidt, U; Wagner, VR, 1975
)
0.25
" It is concluded that UDCA appears to be safe only in stages I to III and that prognostic stratification based on bile acid levels or on the histological stage of the disease should be an important aspect of controlled clinical trials."( Ursodeoxycholic acid in primary biliary cirrhosis: no evidence for toxicity in the stages I to III.
Bircher, J; Foelsch, UR; Lotterer, E; Raedsch, R; Stiehl, A, 1990
)
0.28
" To determine its safety, the authors summarized data concerning adverse reactions, laboratory parameters, and other assessments for 1,068 adult patients who received gadopentetate dimeglumine in United States clinical trials."( Safety assessment of gadopentetate dimeglumine in U.S. clinical trials.
Blumenfield, DM; Blumetti, RF; Goldstein, HA; Holyoak, WL; Hugo, FP; Kashanian, FK, 1990
)
0.28
" The hypotensive side effect can be used for treatment of reactive arterial hypertension in neurosurgical patients during surgery where this therapy is advantageous per se because of its cerebral dehydrating effects."( [Acute lowering of blood pressure by infusion of hyperosmolal sorbitol solution in brain operations. Dangerous adverse effect or favorable side effect?].
Panning, B; Piepenbrock, S; Schäffer, J; Stolke, D, 1988
)
0.27
" Also, glycerol at high osmolality was not toxic and did not induce aberrations, probably because rapid equilibration across the cell membrane precluded severe osmotic stress to the cells."( Effects of high osmotic strength on chromosome aberrations, sister-chromatid exchanges and DNA strand breaks, and the relation to toxicity.
Armstrong, MJ; Bean, CL; Bradley, MO; Deasy, DA; Galloway, SM; Kraynak, AR, 1987
)
0.27
"The influence of the free radical scavenger 2,4-tetra-O-methyl-furfurylidene-sorbitol (MSF) on the carrageenan-induced hind-paw inflammation in rats as well as its influence on the anti-inflammatory and toxic activities of indomethacin is evaluated in comparison with thiola, thioctic acid, silymarin, reduced glutathione and propylgallate."( Influence of 2,4-tetra-O-methyl-furfurylidene-sorbitol (MSF) on carrageenan-induced inflammation and anti-inflammatory and toxic effects of indomethacin in rats.
Baggio, G; Poggioli, R; Zanoli, P, 1982
)
0.26
" The possible importance of alpha-tocopherol in preventing the toxic effect of iron on the apparently very sensitive myocardium after parenteral iron to patients with severe malabsorption syndrome is discussed."( Alpha-tocopherol and cardiac toxicity of iron.
Lindvall, S; Rydén, L; Smedgärd, P; Swedberg, B, 1980
)
0.26
" The drug was only slightly toxic to BRP but induced morphological changes in pericytes with the loss of cellular processes and decreased cell spreading."( The effect of aminoguanidine and tolrestat on glucose toxicity in bovine retinal capillary pericytes.
Chibber, R; Kohner, EM; Mirlees, D; Molinatti, PA; Wong, JS, 1994
)
0.29
" During the maintenance phase (period of epoetin therapy after correction of iron deficiency), the use of low-dose intravenous iron supplementation (10 to 20 mg per haemodialysis treatment or 100 mg every second week) avoids iron overtreatment and minimises potential adverse effects."( Safety aspects of parenteral iron in patients with end-stage renal disease.
Hörl, WH; Sunder-Plassmann, G, 1997
)
0.3
" The aim of this study was to quantitatively assess spontaneous functional hepatic arteriovenous shunting in patients with liver metastases and to determine its implication in the increase in systemic toxic effects of intra-arterial infusion chemotherapy with floxuridine."( Sorbitol removal by the metastatic liver: a predictor of systemic toxicity of intra-arterial chemotherapy in patients with liver metastases.
Alabiso, O; Bar, F; Battista, S; Bucchi, MC; Cappello, N; Gariboldi, A; Grosso, M; Miraglia, S; Molino, G; Zanon, C, 1999
)
0.3
"There were no adverse effects attributable to the use of the irrigant."( Sorbitol-mannitol solution for urological electrosurgical resection-- a safer fluid than glycine 1.5%.
Dawkins, GP; Miller, RA, 1999
)
0.3
" The aim of our study was to predict the occurrence of systemic toxic effects from this treatment using a scintigraphic and pharmacokinetic approach."( Hepatic arterial infusion chemotherapy for unresectable confined liver metastases: prediction of systemic toxicity with the application of a scintigraphic and pharmacokinetic approach.
Alabiso, O; Bar, F; Battista, S; Bellò, M; Bisi, G; Bucchi, MC; Molino, G; Pelosi, E, 1999
)
0.3
" Treatment was then started and systemic toxic effects were evaluated according to WHO recommendations."( Hepatic arterial infusion chemotherapy for unresectable confined liver metastases: prediction of systemic toxicity with the application of a scintigraphic and pharmacokinetic approach.
Alabiso, O; Bar, F; Battista, S; Bellò, M; Bisi, G; Bucchi, MC; Molino, G; Pelosi, E, 1999
)
0.3
" Addition of polyamines prevents the toxic effect of oxygen, permitting cell survival and optimal growth."( Polyamines protect Escherichia coli cells from the toxic effect of oxygen.
Chattopadhyay, MK; Tabor, CW; Tabor, H, 2003
)
0.32
" However, AmB-M seemed to be much more toxic than AmB-LP."( Decrease in Fungizone toxicity induced by the use of Lipofundin as a dilutent: an in vitro study.
Damasceno, BP; de Araújo, IB; de Medeiros, TM; do Egito, ES; Soares, LA, 2005
)
0.33
" Five participants discontinued the study due to adverse events, including myalgia, muscle spasm, and muscle fatigue."( Pharmacokinetics, pharmacodynamics, tolerability, and safety of a novel sorbitol dehydrogenase inhibitor in healthy participants.
Calle, RA; Dai, H; Freeman, T; Landau, Z; Novotny, MJ; Oates, PJ; Preston, GM; Thompson, J; Wright, K, 2010
)
0.36
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
"Transcervical resection of myomas (TCR-M) is considered a safe hysteroscopic procedure if intravasation is limited."( How safe is the intravasation limit in hysteroscopic surgery?
de Haan, P; France, C; Rademaker, BM; Rademaker, D; van Kesteren, PJ,
)
0.13
" However, its use has been associated with colonic necrosis and other fatal gastrointestinal adverse events."( Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review.
Bell, CM; Harel, S; Harel, Z; Perl, J; Shah, PS; Wald, R, 2013
)
0.39
"MEDLINE (1948 to July 2011), EMBASE (1980 to July 2011), Cochrane Central Register of Controlled Trials (CENTRAL) (1993 to July 27, 2011), bibliographies of identified articles, and websites of relevant drug agencies and professional associations in the United States and Canada were reviewed to identify eligible reports of adverse gastrointestinal events associated with sodium polystyrene sulfonate use."( Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review.
Bell, CM; Harel, S; Harel, Z; Perl, J; Shah, PS; Wald, R, 2013
)
0.39
"Thirty reports describing 58 cases (41 preparations containing sorbitol and 17 preparations without sorbitol) of adverse events were identified."( Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review.
Bell, CM; Harel, S; Harel, Z; Perl, J; Shah, PS; Wald, R, 2013
)
0.39
" Physicians must be cognizant of the risk of these adverse events when prescribing this therapy for the management of hyperkalemia."( Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review.
Bell, CM; Harel, S; Harel, Z; Perl, J; Shah, PS; Wald, R, 2013
)
0.39
"There were no serious adverse events, adverse events leading to discontinuation, or episodes of hypoglycemia."( Safety, pharmacokinetics, and pharmacodynamics of single and multiple luseogliflozin dosing in healthy Japanese males: a randomized, single-blind, placebo-controlled trial.
Fukatsu, A; Sakai, S; Samukawa, Y; Sasaki, T; Seino, Y, 2014
)
0.4
" There were no significant differences in the incidences of adverse events among groups."( Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, placebo-controlled, phase II study.
Fukatsu, A; Sakai, S; Samukawa, Y; Sasaki, T; Seino, Y, 2014
)
0.4
" Safety assessments included adverse events (AEs), clinical laboratory tests, and vital signs."( Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study.
Fukatsu, A; Sakai, S; Samukawa, Y; Sasaki, T; Seino, Y; Ubukata, M, 2014
)
0.4
" Seven patients had mild adverse events (AEs); all were resolved."( Pharmacokinetics, Pharmacodynamics, and Safety of Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized, Single-blind, Placebo-controlled Trial.
Fukatsu, A; Sakai, S; Samukawa, Y; Sasaki, T; Seino, Y; Ubukata, M, 2015
)
0.42
" The safety end points included adverse events (AEs) and laboratory parameters."( Influence of Renal Function on the 52-Week Efficacy and Safety of the Sodium Glucose Cotransporter 2 Inhibitor Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus.
Fukatsu, A; Haneda, M; Inagaki, N; Kakiuchi, H; Kaku, K; Sakai, S; Samukawa, Y; Sasaki, T; Sato, Y; Seino, Y, 2016
)
0.43
" In safety, the incidence of adverse events was similar between groups, and most of them were mild in severity."( Efficacy and Safety of the SGLT2 Inhibitor Luseogliflozin in Japanese Patients With Type 2 Diabetes Mellitus Stratified According to Baseline Body Mass Index: Pooled Analysis of Data From 52-Week Phase III Trials.
Fukatsu, A; Haneda, M; Inagaki, N; Kakiuchi, H; Kaku, K; Sakai, S; Samukawa, Y; Sasaki, T; Seino, Y, 2016
)
0.43
" As these agents have a considerably different glucose-lowering mechanism from those of other anti-diabetic drugs, safe use of this drug class needs to be discussed based on data available from preapproval clinical trials as well as real-world studies."( Sodium glucose co-transporter 2 inhibitor luseogliflozin in the management of type 2 diabetes: a drug safety evaluation.
Hamamoto, Y; Kurose, T; Kuwata, H; Seino, Y; Yabe, D, 2017
)
0.46
" Safety assessments included adverse events, laboratory tests and vital signs."( Efficacy and safety of luseogliflozin added to insulin therapy in Japanese patients with type 2 diabetes: a multicenter, 52-week, clinical study with a 16-week, double-blind period and a 36-week, open-label period.
Fukatsu, A; Imazeki, H; Ochiai, H; Sakai, S; Sasaki, T; Seino, Y, 2018
)
0.48
" Most adverse events were mild in severity."( Efficacy and safety of luseogliflozin added to insulin therapy in Japanese patients with type 2 diabetes: a multicenter, 52-week, clinical study with a 16-week, double-blind period and a 36-week, open-label period.
Fukatsu, A; Imazeki, H; Ochiai, H; Sakai, S; Sasaki, T; Seino, Y, 2018
)
0.48
" However, its therapeutic index is narrow, and it is prone to adverse side effects, along with an increased risk of toxicity, namely, cardio-, nephro-, hepato-, and neurotoxicity."( The effect of tacrolimus-induced toxicity on metabolic profiling in target tissues of mice.
Dang, R; Guo, J; Han, W; Li, Y; Meng, J; Si, Q; Wang, S; Wei, N; Wu, L; Xie, D, 2022
)
0.72

Pharmacokinetics

No difference in the effect on phenytoin pharmacokinetic parameters was noted when the charcoal was administered with or without sorbitol. Fewer gastrointestinal adverse effects were noted without Sorbitol treatment.

ExcerptReferenceRelevance
" Plasma drug concentrations were measured by HPLC or liquid scintillation spectrometry and various pharmacokinetic parameters (clearance, CL; Vd, volume of distribution; and t1/2) were calculated from the data."( Interspecies comparison of the pharmacokinetics of aldose reductase inhibitors.
Barker, R; Brazzell, RK; Couch, R; McCue, B; Park, YH; Wooldridge, CB; York, B,
)
0.13
" No difference in the effect on phenytoin pharmacokinetic parameters was noted when the charcoal was administered with or without sorbitol, but fewer gastrointestinal adverse effects were noted without sorbitol treatment."( The effect of activated charcoal on phenytoin pharmacokinetics.
Bertino, JS; Rowden, AM; Spoor, JE, 1990
)
0.28
"Oral activated charcoal was shown to affect phenytoin pharmacokinetic parameters."( The effect of activated charcoal on phenytoin pharmacokinetics.
Bertino, JS; Rowden, AM; Spoor, JE, 1990
)
0.28
" Experiments with lipophilic LMWH tracer bound nonspecifically to rat serum albumin confirmed that the prolonged half-life might in part be due to an increased affinity for albumin."( Altered pharmacokinetic properties of a lipophilically derivatized low-molecular-weight heparin in rats.
Dempfle, CE; Friedrich, EA; Harenberg, J; Heene, DL; Maier-Borst, W; Peschke, P; Schrenk, HH; Sinn, H; Stehle, G; Wunder, A, 1993
)
0.29
" The enantiomers had differing pharmacokinetic profiles, while the racemic compound exhibited pharmacokinetic parameters approximating the mean values of the individual enantiomers."( Comparison of the pharmacokinetics and pharmacodynamics of the aldose reductase inhibitors, AL03152 (RS), AL03802 (R), and AL03803 (S).
Barker, R; DuPriest, M; Griffin, BW; Mayer, PR; Park, YH; Slattery, JT; Williams, GW; York, BM, 1993
)
0.29
"To examine the effect of diabetes mellitus on the pharmacokinetics of tolrestat and to investigate its effect on red blood cell sorbitol levels according to a new pharmacodynamic model for this class of drugs."( Tolrestat pharmacokinetic and pharmacodynamic effects on red blood cell sorbitol levels in normal volunteers and in patients with insulin-dependent diabetes.
Chiang, ST; Cohen, AF; Jusko, WJ; Kroon, R; Lemkes, HH; van Griensven, JM; Verhorst, CJ, 1995
)
0.29
"Tolrestat disposition was characterized by first-order absorption and biexponential disposition: In normal subjects the terminal disposition half-life (t1/2) was 13 +/- 3 hours (mean +/- SD) and the apparent oral clearance (CL/F) was 48 +/- 9 ml/hr/kg, similar to the values in patients with type I diabetes mellitus (t1/2 = 14 +/- 4 hours; CL/F = 55 +/- 10 ml/hr/kg)."( Tolrestat pharmacokinetic and pharmacodynamic effects on red blood cell sorbitol levels in normal volunteers and in patients with insulin-dependent diabetes.
Chiang, ST; Cohen, AF; Jusko, WJ; Kroon, R; Lemkes, HH; van Griensven, JM; Verhorst, CJ, 1995
)
0.29
" The peak concentration of serum triglyceride was smaller in MCT group."( [A comparative study of fat emulsions clearance test using long chain triglycerides and medium chain triglycerides in volunteers].
He, G; Jiang, Z; Shu, H; Wang, X, 1995
)
0.29
" 230 l), and the half-life was slightly increased (19."( Influence of age, frailty and liver function on the pharmacokinetics of brofaromine.
Antonin, KH; Bergmann, W; Bieck, P; Degel, F; Fuchs, L; Platt, D; Zeeh, J, 1996
)
0.29
" The derived pharmacokinetic variables were not different among formulations."( Pharmacokinetics and pharmacodynamics of propofol in a new solvent.
Babl, J; Doenicke, AW; Klotz, U; Kugler, J; O'Connor, M; Rau, J; Roizen, MF, 1997
)
0.3
"5-30 Hz) as pharmacodynamic endpoint."( Influence of different fat emulsion-based intravenous formulations on the pharmacokinetics and pharmacodynamics of propofol.
Cox, EH; Danhof, M; Knibbe, CA; Koster, VS; Kuks, PF; Lange, R; Langemeijer, HJ; Langemeijer, MW; Lie-A-Huen, L; Tukker, EE, 1998
)
0.3
"Following bolus infusion, the pharmacokinetics of the various propofol emulsions could adequately be described by a two-compartmental pharmacokinetic model."( Influence of different fat emulsion-based intravenous formulations on the pharmacokinetics and pharmacodynamics of propofol.
Cox, EH; Danhof, M; Knibbe, CA; Koster, VS; Kuks, PF; Lange, R; Langemeijer, HJ; Langemeijer, MW; Lie-A-Huen, L; Tukker, EE, 1998
)
0.3
" The aim of our study was to predict the occurrence of systemic toxic effects from this treatment using a scintigraphic and pharmacokinetic approach."( Hepatic arterial infusion chemotherapy for unresectable confined liver metastases: prediction of systemic toxicity with the application of a scintigraphic and pharmacokinetic approach.
Alabiso, O; Bar, F; Battista, S; Bellò, M; Bisi, G; Bucchi, MC; Molino, G; Pelosi, E, 1999
)
0.3
"A protocol combining scintigraphic and pharmacokinetic methods is of value in the individual patient in assessing the risk of high-grade systemic toxicity during hepatic arterial infusion of floxuridine."( Hepatic arterial infusion chemotherapy for unresectable confined liver metastases: prediction of systemic toxicity with the application of a scintigraphic and pharmacokinetic approach.
Alabiso, O; Bar, F; Battista, S; Bellò, M; Bisi, G; Bucchi, MC; Molino, G; Pelosi, E, 1999
)
0.3
"In pharmacokinetic studies of hepatic impairment, including all classes of cirrhosis may be more revealing than including only selected classes of liver failure."( Pharmacokinetics of levetiracetam in patients with moderate to severe liver cirrhosis (Child-Pugh classes A, B, and C): characterization by dynamic liver function tests.
Brockmöller, J; Coupez, R; Lochs, H; Roots, I; Thomsen, T; Wittstock, M, 2005
)
0.33
" The simulations reveal that the expanded models exhibit most properties of basic indirect response models, such as slow response initiation, lag time between the kinetic and dynamic peaks, a large dose plateau, and shift in Tmax with dose."( Assessment of basic indirect pharmacodynamic response models with physiological limits.
Jusko, WJ; Krzyzanski, W; Yao, Z, 2006
)
0.33
" Alfentanil pharmacokinetics (plasma concentration, area under the plasma concentration-time curve from time zero to infinity [AUC(infinity(p))] and from time zero to 2 hours [AUC(2(p))], apparent volume of distribution at steady state, clearance and terminal elimination half-life [t((1/2)(p))]) and miosis pseudo-kinetic parameters [AUC(infinity)((miosis)), AUC(2)((miosis)), t((1/2))((miosis))] were determined using a noncompartmental analysis method."( Alfentanil-induced miosis as a surrogate measure of alfentanil pharmacokinetics in patients with mild and moderate liver cirrhosis.
Baririan, N; Desager, JP; Horsmans, Y; Starkel, P; Van Obbergh, L; Verbeeck, RK; Wallemacq, P, 2007
)
0.34
"Alfentanil pharmacokinetic parameters were correlated with miosis pseudo-kinetic parameters in cirrhotic patients."( Alfentanil-induced miosis as a surrogate measure of alfentanil pharmacokinetics in patients with mild and moderate liver cirrhosis.
Baririan, N; Desager, JP; Horsmans, Y; Starkel, P; Van Obbergh, L; Verbeeck, RK; Wallemacq, P, 2007
)
0.34
" V was applied for propofol pharmacokinetic analysis."( Pilot study on the influence of liver blood flow and cardiac output on the clearance of propofol in critically ill patients.
Aarts, LP; Boom, FA; Bras, LJ; Danhof, M; Knibbe, CA; Peeters, MY; Tibboel, D, 2008
)
0.35
" Twenty-four swine were treated with 1× dose for pharmacokinetic analysis through 30 days."( Vascular, downstream, and pharmacokinetic responses to treatment with a low dose drug-coated balloon in a swine femoral artery model.
Kolodgie, FD; Ladich, E; Naisbitt, S; Nakano, M; Otsuka, F; Pacheco, E; Rousselle, S; Virmani, R; Yazdani, SK, 2014
)
0.4
"Luseogliflozin was well tolerated and showed favorable pharmacokinetic and pharmacodynamic profiles in healthy male Japanese subjects."( Safety, pharmacokinetics, and pharmacodynamics of single and multiple luseogliflozin dosing in healthy Japanese males: a randomized, single-blind, placebo-controlled trial.
Fukatsu, A; Sakai, S; Samukawa, Y; Sasaki, T; Seino, Y, 2014
)
0.4
" The pharmacokinetic and pharmacodynamic profile of luseogliflozin observed in this study supports its once-daily dosing regimen."( Pharmacokinetics, Pharmacodynamics, and Safety of Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized, Single-blind, Placebo-controlled Trial.
Fukatsu, A; Sakai, S; Samukawa, Y; Sasaki, T; Seino, Y; Ubukata, M, 2015
)
0.42
" Duration and onset of the pharmacologic effects seemed to be closely correlated with the pharmacokinetic properties of each SGLT2 inhibitor, particularly with respect to high distribution and long retention in the target organ, the kidney."( Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects.
Imamura, M; Kurosaki, E; Tahara, A; Takasu, T; Yokono, M, 2016
)
0.43
" Serial blood sampling over 72 hours and 24-hour urine collection were done for pharmacokinetic analysis of luseogliflozin and its metabolites and to measure pharmacokinetic and pharmacodynamic parameters, respectively."( Luseogliflozin, an SGLT2 Inhibitor, in Japanese Patients With Mild/Moderate Hepatic Impairment: A Pharmacokinetic Study.
Furihata, K; Ito, T; Kumagai, Y; Ochiai, H; Sakai, S; Samukawa, Y; Sata, M; Ueda, N, 2017
)
0.46

Compound-Compound Interactions

Three trials were conducted with finishing steers to study the effect of feeding sorbitol alone or combined with monensin. We used the Trive 1000 (EGIC Laboratories) which is a soya oil emulsion combined with essential amino-acides and with Sorbitol.

ExcerptReferenceRelevance
" We used the Trive 1000 (EGIC Laboratories) which is a soya oil emulsion combined with essential amino-acides and with Sorbitol."( [Impact, on blood and tissue lipids, of an artificial lipid emulsion combined with essential amino acids and sorbitol, used in humans in exclusive parenteral feeding].
Dewailly, P; Fruchart, JC; Nouvelot, A; Plouvier, B; Scherperel, P, 1976
)
0.26
" A study was done in volunteers to determine the rapidity of gastrointestinal transit when activated charcoal was administered with various cathartics."( Gastrointestinal transit times of cathartics combined with charcoal.
Keller, R; Krenzelok, EP; Stewart, RD, 1985
)
0.27
"Three trials were conducted with finishing steers to study the effect of feeding sorbitol alone or combined with monensin."( Feeding sorbitol alone or in combination with monensin to finishing cattle.
Fontenot, JP; Huchette, HM, 1993
)
0.29
"This study investigated whether aldose reductase (AR) inhibition with zopolrestat, either alone or in combination with an adenosine A(3)-receptor agonist (CB-MECA), reduced myocardial ischemic injury in rabbit hearts subjected to 30 min of regional ischemia and 120 min of reperfusion."( Aldose reductase inhibition alone or combined with an adenosine A(3) agonist reduces ischemic myocardial injury.
Ellery, CA; Knight, DR; MacAndrew, JT; Magee, WP; Oates, PJ; Smith, AH; Tracey, WR, 2000
)
0.31
" The purpose of this study was to investigate metabolic changes in the rabbit lens after long-term dexamethasone treatment in combination with UVB exposure, using high-resolution magic angle spinning proton nuclear magnetic resonance (HR-MAS (1)H NMR) spectroscopy to analyse intact lens tissues."( High-resolution magic angle spinning 1H NMR spectroscopy of metabolic changes in rabbit lens after treatment with dexamethasone combined with UVB exposure.
Cejková, J; Krane, J; Midelfart, A; Risa, O; Saether, O, 2004
)
0.32
" Long-term treatment with dexamethasone combined with UVB exposure induced substantial metabolic changes, dominated by osmolytic regulation processes and loss of glutathione."( High-resolution magic angle spinning 1H NMR spectroscopy of metabolic changes in rabbit lens after treatment with dexamethasone combined with UVB exposure.
Cejková, J; Krane, J; Midelfart, A; Risa, O; Saether, O, 2004
)
0.32
"The aim of the current study was to evaluate a multiplex PCR (mPCR) detection test combined with the evaluation of a previously described isolation method."( Evaluation of a multiplex-PCR detection in combination with an isolation method for STEC O26, O103, O111, O145 and sorbitol fermenting O157 in food.
De Reu, K; De Rijk, P; De Zutter, L; Del-Favero, J; Herman, L; Heyndrickx, M; Joris, MA; Robyn, J; Verstraete, K, 2012
)
0.38
" Among these, an innovative viscosupplement has been produced from high a concentration of HA combined with a high concentration of sorbitol as a free radical scavenger."( Duration of symptom relief after intra-articular injection of hyaluronic acid combined with sorbitol (anti-ox-vs) in symptomatic hip osteoarthritis.
Bizzi, E; Cassol, M; Granata, M; Massafra, U; Migliore, A; Tormenta, S,
)
0.13
"A strategy for assessing potential drug-drug interactions (DDIs) based on a simulated intestinal concentration is described."( A Strategy for assessing potential drug-drug interactions of a concomitant agent against a drug absorbed via an intestinal transporter in humans.
Gunji, E; Jingu, S; Kinoshita, K; Mizuno-Yasuhira, A; Nakai, Y; Sakai, S; Samukawa, Y; Takahashi, T; Uchida, S; Yamaguchi, J, 2014
)
0.4
"We investigated the possibilities of drug-drug interactions between luseogliflozin, a sodium-glucose co-transporter-2 inhibitor, and oral antidiabetic drugs (OADs) in healthy Japanese males."( Absence of Drug-Drug Interactions Between Luseogliflozin, a Sodium-Glucose Co-transporter-2 Inhibitor, and Various Oral Antidiabetic Drugs in Healthy Japanese Males.
Fukatsu, A; Sakai, S; Samukawa, Y; Sasaki, T; Seino, Y; Ubukata, M, 2015
)
0.42

Bioavailability

D-sorbitol bioavailability in cirrhotic patients was not significantly affected by the inclusion of 10% (w/v) D-Sorbitol or increase of pH to 3. In a control group of 20 women given neither sorbitol nor glucose, the mean +/- SEM fractional radiocalcium absorption rate from a low carrier load was 0.

ExcerptReferenceRelevance
" The results from these preliminary studies suggests normal bioavailability of this material for Hb-synthesis."( Studies on iron stores built up by an iron-poly (sorbitol-gluconic acid) complex, Ferastral, in man. Preliminary report.
Olsson, KS, 1977
)
0.26
" It is suggested that this fraction comprises the smaller molecular species of the Ferastral complex and that these species have a faster rate of absorption from an intramuscular injection site than the larger molecular species of the iron complex preparation."( Interaction between Ferastral and plasma factors.
Doney, V; Fielding, J, 1977
)
0.26
" Thereafter, the absorption rate is slower, and 32 days after the injection 94% has been absorbed from the injection site."( Studies on an iron-poly(sorbitol-gluconic acid) complex for parenteral treatment of iron deficiency anaemia.
Domeij, K; Hellström, V; Högberg, KG; Lindvall, S; Ortengren, B; Rydell, G; Wichman, U, 1977
)
0.26
" At a physiological low level of maltitol intake, the results also indicated an insignificant calorie-saving effect in comparison to sucrose, an effect based mainly on the slow absorption rate of the maltitol cleavage product sorbitol."( Gastrointestinal transit and digestibility of maltitol, sucrose and sorbitol in rats: a multicompartmental model and recovery study.
Grossklaus, R; Herold, M; Klingebiel, L; Krüger, D; Lorenz, S, 1992
)
0.28
" The bioavailability of an investigational drug in cynomolgus monkeys could be enhanced sevenfold by inclusion complexation with 2-HP-beta-CD."( Effect of hydrotropic substances on the complexation of sparingly soluble drugs with cyclodextrin derivatives and the influence of cyclodextrin complexation on the pharmacokinetics of the drugs.
Albers, E; Müller, BW, 1991
)
0.28
" Twenty-five normal subjects and 50 cirrhotic patients were studied in order to assess if the measure of the plasma disappearance rate of sorbitol can be used as a simpler procedure to evaluate changes in liver perfusion and to predict modifications of drug bioavailability due to circulatory events."( D-sorbitol plasma disappearance rate: an index to evaluate changes in liver circulation.
Aurucci, PE; Avagnina, P; Ballarè, M; Cavanna, A; Molino, G; Niro, AG; Torchio, M,
)
0.13
"01) reduced the peak plasma concentration and oral bioavailability of SP."( Effects of activated charcoal and sorbitol on sodium pentobarbital absorption in the rat.
Bordelon, JG; Curd-Sneed, CD; Parks, KS; Stewart, JJ, 1987
)
0.27
" The present results suggest that 5-ISMN shows a high bioavailability and a potency comparable to ISDN, especially in the case of peroral administration."( [Effects of isosorbide 5-mononitrate on cardiovascular function. (I). Effects on the left ventricular system].
Kogi, K; Saito, T, 1985
)
0.27
" Our results demonstrate the systemic bioavailability of tolrestat and its aldose reductase inhibitory activity in erythrocytes of patients with diabetes."( Effect of tolrestat on red blood cell sorbitol levels in patients with diabetes.
Challis, P; Dvornik, D; Gonzalez, R; Hicks, D; Mullane, JF; Raskin, P; Rosenstock, J; Ryder, S; Smith, T, 1985
)
0.27
"For the sake of metabolic insight into the fate of the sugar substitute Palatinit, its two components D-glucosyl-alpha (1 leads to 1)-D-mannitol and D-glucosyl-alpha (1 leads to 6)-D-glucitol [D-glucosyl-alpha-(1 leads to 6)-D-sorbitol] were assayed for glucose bioavailability by the procedure of Karimzadegan et al."( Bioavailability of glucose from Palatinit.
Ziesenitz, SC, 1983
)
0.27
" The increased gentamicin bioavailability in response to sodium salicylate adjuvant activity appeared to be independent of and additive to the increased gentamicin absorption due to high ionic strength conditions."( Influence of ionic strength on rectal absorption of gentamicin sulfate in the presence and absence of sodium salicylate.
Caldwell, LJ; Fix, JA; Leppert, PS; Porter, PA, 1983
)
0.27
" By modulating the bioavailability of nicotinic acid, sorbinicate maintains and in some cases enhances the pharmacological activity of the acid, avoiding at least some of its major side effects."( Comparative evaluation of some pharmacological properties and side effects of D-glucitol hexanicotinate (sorbinicate) and nicotinic acid correlated with the plasma concentration of nicotinic acid.
Biagi, M; Sardelli, G; Schiantarelli, P; Subissi, A, 1980
)
0.26
"Because sorbitol is poorly absorbed in the small intestine, it may be the origin of large amounts of residues reaching the large intestine and may be substrate for microbial activity."( Absorption balances and kinetics of nutrients and bacterial metabolites in conscious pigs after intake of maltose- or maltitol-rich diets.
Giusi-Périer, A; Rérat, A; Vaissade, P, 1993
)
0.29
" The fractional bioavailability (Fma) of D-sorbitol was calculated as the ratio between the net cumulative urinary outputs obtained after infusion through the catheter into the superior mesenteric artery and the systemic vein, respectively."( Determination of functional portal-systemic shunting in patients submitted to hepatic angiography.
Avagnina, P; Bar, F; Battista, S; Garello, E; Grosso, M; Molino, G; Spalluto, F, 1996
)
0.29
" No clinical studies have been published to investigate the ability of a cathartic, with or without activated charcoal, to reduce the bioavailability of drugs or to improve the outcome of poisoned patients."( Position statement: cathartics. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists.
Barceloux, D; Hartigan-Go, K; McGuigan, M, 1997
)
0.3
" Because of this property, the systemic bioavailability of D-sorbitol during hepatic arterial infusion can be assumed to reflect arterial-venous shunting."( Arterial-venous shunting in liver cirrhosis.
Avagnina, P; Bar, F; Battista, S; Fava, C; Garello, E; Grosso, M; Molino, G; Niro, AG; Spalluto, F; Torchio, M, 1998
)
0.3
" Pharmacokinetic studies suggested that SG-210 has a high bioavailability and possesses a long half-life in rats (ca."( Effect of SG-210, a novel aldose reductase inhibitor, on impaired polyol pathway in rats received diabetic manipulations.
Horie, S; Nagai, H; Nakajima, T; Nakamura, N; Narita, Y; Tsuda, Y; Yuuki, T,
)
0.13
"In this study a mathematical model was applied to predict how changes in hepatic extraction ratio (E), fractional portal inflow (P) and renal elimination ratio (R) may affect fractional D-sorbitol bioavailability in cirrhotic patients."( Prediction by mathematical simulation of different pathophysiological effects on D-sorbitol bioavailability.
Bar, F; Battista, S; Molino, G; Torchio, M, 1998
)
0.3
" Functional hepatic arterio-venous shunting was evaluated through the bioavailability of intra-arterially administered D-sorbitol, a safe, natural compound whose kinetic features make its hepatic clearance flow dependent."( Sorbitol removal by the metastatic liver: a predictor of systemic toxicity of intra-arterial chemotherapy in patients with liver metastases.
Alabiso, O; Bar, F; Battista, S; Bucchi, MC; Cappello, N; Gariboldi, A; Grosso, M; Miraglia, S; Molino, G; Zanon, C, 1999
)
0.3
"Our results show that, in the metastatic liver, arterial bioavailability of D-sorbitol, an index of functional arteriovenous shunting, varies widely, is significantly greater in patients with massive liver occupation and it is a good predictor of systemic toxicity of intra-arterial regional chemotherapy with floxuridine."( Sorbitol removal by the metastatic liver: a predictor of systemic toxicity of intra-arterial chemotherapy in patients with liver metastases.
Alabiso, O; Bar, F; Battista, S; Bucchi, MC; Cappello, N; Gariboldi, A; Grosso, M; Miraglia, S; Molino, G; Zanon, C, 1999
)
0.3
" Hepatic arteriovenous functional shunting was assessed through the bioavailability of intraarterially administered D-sorbitol."( Hepatic arterial infusion chemotherapy for unresectable confined liver metastases: prediction of systemic toxicity with the application of a scintigraphic and pharmacokinetic approach.
Alabiso, O; Bar, F; Battista, S; Bellò, M; Bisi, G; Bucchi, MC; Molino, G; Pelosi, E, 1999
)
0.3
" A double-blind, placebo-controlled study compared the effects of sorbitol (40 g/day in candy), a poorly absorbed sugar-alcohol with known osmotic effects, with those of olestra (20 or 40 g/day in potato chips), a nonabsorbed fat, on objective measures of stool composition and GI symptoms."( Effects of olestra and sorbitol consumption on objective measures of diarrhea: impact of stool viscosity on common gastrointestinal symptoms.
Bishop, L; Filloon, T; Giannella, R; McRorie, J; Riccardi, K; Wason, S; Zorich, N, 2000
)
0.31
" The beneficial effect observed in the T group compared with the C group was apparently mostly due to the administration mode via FAP, which could prolong the intra-oral bioavailability of the prophylactic preparation."( Efficacy of a slow-release device containing fluoride, xylitol and sorbitol in preventing infant caries.
Aaltonen, AS; Inkilä-Saari, I; Suhonen, JT; Tenovuo, J, 2000
)
0.31
"Fractional systemic bioavailability of orally administered drugs was found to be unexpectedly low in liver cirrhosis, even after surgical portal-systemic shunting."( Time-dependent modifications of splanchnic circulation in female pigs submitted to end-to-side portacaval anastomosis.
Avagnina, P; Bianco, S; Degerfeld, MM; Garrone, C; Molino, G; Peretti, P; Sansoè, G; Tinivella, M, 2001
)
0.31
" The bioavailability of ADiSP and a native (unmodified) starch was evaluated in 20 normal infants and 21 toddlers aged 8-24 mo with chronic non-specific diarrhea."( Malabsorption of modified food starch (acetylated distarch phosphate) in normal infants and in 8-24-month-old toddlers with non-specific diarrhea, as influenced by sorbitol and fructose.
Lebenthal, A; Lebenthal, E; Lebenthal-Bendor, Y; Tabi, I; Theuer, RC, 2001
)
0.31
" Based on these observations, we suggest that NO regulates the vascular synthesis of polyols by S-thiolating AR; therefore, increasing NO synthesis or bioavailability may be useful in preventing diabetes-induced changes in the polyol pathway."( Nitric oxide regulates the polyol pathway of glucose metabolism in vascular smooth muscle cells.
Bhatnagar, A; Chandra, D; Ramana, KV; Srivastava, S; Srivastava, SK, 2003
)
0.32
" These results suggest that excessive NO contributes to hemorrhage-induced tissue inflammation and that reducing the bioavailability of NO using NOX may be beneficial in HS."( Reduced hepatic transcription factor activation and expression of IL-6 and ICAM-1 after hemorrhage by NO scavenging.
Billiar, TR; Harbrecht, B; Hierholzer, C; Tweardy, DJ, 2003
)
0.32
" It is well absorbed in rats (oral bioavailability, 98%) and has a long plasma t(1/2) (26 +/- 3 h)."( A highly selective, non-hydantoin, non-carboxylic acid inhibitor of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3-methylbenzofuran- 2-sulfonyl)-2-H-pyridazin-3-one.
Armento, SJ; Beebe, DA; Conn, EL; Coutcher, JB; Dina, MS; Linhares, MC; Martin, WH; Mylari, BL; O'Gorman, MT; Oates, PJ; Tess, DA; Withbroe, GJ; Zembrowski, WJ, 2003
)
0.32
"In 25 patients with untreated celiac disease and 23 sex- and age-matched healthy volunteers, breath H(2) excretion was measured after ingestion of a 250-ml solution containing sorbitol, a poorly absorbed alcohol sugar."( Mixing of the intestinal content and variations of fermentation capacity do not affect the results of hydrogen breath test.
Corazza, GR; Di Stefano, M; Malservisi, S; Miceli, E; Missanelli, A; Strocchi, A, 2003
)
0.32
" No clinical studies have been published to investigate the ability of a cathartic, with or without activated charcoal, to reduce the bioavailability of drugs or to improve the outcome of poisoned patients."( Position paper: cathartics.
, 2004
)
0.32
" In rats, its oral bioavailability is 98% and it has a favorable plasma t(1/2) (26 +/- 3 h)."( A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3-methylbenzofuran-2-sulfonyl)-2H-pyridazin-3-one and congeners.
Armento, SJ; Beebe, DA; Conn, EL; Coutcher, JB; Dina, MS; Linhares, MC; Martin, WH; Mylari, BL; O'Gorman, MT; Oates, PJ; Tess, DA; Withbroe, GJ; Zembrowski, WJ, 2005
)
0.33
" This notion, however, has been challenged recently by studies on the bioavailability of flavonoids, which indicate that they reach only very low concentrations in human plasma after the consumption of flavonoid-rich foods."( Consumption of flavonoid-rich foods and increased plasma antioxidant capacity in humans: cause, consequence, or epiphenomenon?
Frei, B; Lotito, SB, 2006
)
0.33
" A urinary excretion pharmacokinetic method was used to evaluate the bioavailability of the selected ternary formulae, inhaled via a Handihaler, relative to the marketed Intal Spincaps, inhaled via a Spinhaler."( Promising ternary dry powder inhaler formulations of cromolyn sodium: formulation and in vitro-in vivo evaluation.
El-laithy, HM; Elbary, AA; Tadros, MI, 2007
)
0.34
" These data suggest that increasing NO bioavailability by L-arginine corrects the major biochemical abnormalities of diabetes."( L-Arginine prevents metabolic effects of high glucose in diabetic mice.
Bhatnagar, A; Kaiserova, K; Ramana, KV; Srivastava, SK; West, MB, 2008
)
0.35
" Recent studies indicate that a diet restricted in fermentable, poorly absorbed carbohydrates, including fructose, fructans (present in wheat and onions), sorbitol, and other sugar alcohols is beneficial, but confirmatory studies are needed."( The role of diet in symptoms of irritable bowel syndrome in adults: a narrative review.
Heizer, WD; McGovern, S; Southern, S, 2009
)
0.35
" Owing to aldose reductase pharmacophore requirements for an acidic proton, most aldose reductase inhibitors contain an acetic acid moiety, ionized at physiological pH, resulting in poor bioavailability of the drugs."( (2-Benzyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-8-yl)-acetic acid: an aldose reductase inhibitor and antioxidant of zwitterionic nature.
Juskova, M; Milackova, I; Snirc, V; Stefek, M; Triantos, N; Tsantili-Kakoulidou, A, 2011
)
0.37
" However, DDB therapeutic effectiveness is restricted by its low oral bioavailability that arises from its poor solubility and dissolution."( Novel diphenyl dimethyl bicarboxylate provesicular powders with enhanced hepatocurative activity: preparation, optimization, in vitro/in vivo evaluation.
Abdelbary, GA; Aburahma, MH, 2012
)
0.38
"The aggregation of tetanus toxoid leads to reduced bioavailability of the vaccine and failure of immunization programmes in many parts of the globe."( Stabilization of tetanus toxoid formulation containing aluminium hydroxide adjuvant against agitation.
Jain, NK; Roy, I; Solanki, VA, 2012
)
0.38
" The film formula of choice gave a significantly faster drug absorption rate and recorded a relative bioavailability of 204."( Fast-dissolving sublingual films of terbutaline sulfate: formulation and in vitro/in vivo evaluation.
El-Milligi, MF; Ibrahim, HK; Mohamed, MI; Sayed, S, 2013
)
0.39
" However, low peroral bioavailability is a major limiting factor for the success of clinical utilization of curcumin."( Efficacy of biodegradable curcumin nanoparticles in delaying cataract in diabetic rat model.
Balakrishna, N; Grama, CN; Kumar, MN; Patil, MA; Raghu, G; Reddy, GB; Suryanarayana, P, 2013
)
0.39
"Recently a zwitterionic principle has been suggested as an alternative to bioisosteric replacement for increasing low bioavailability of aldose reductase inhibitors bearing an acidic function."( A novel zwitterionic inhibitor of aldose reductase interferes with polyol pathway in ex vivo and in vivo models of diabetic complications.
Karasova, MJ; Prnova, MS; Stefek, M, 2014
)
0.4
" [14C]Luseogliflozin was rapidly and well absorbed (>86% of the dose) after oral administration to rats and dogs."( Preclinical metabolism and disposition of luseogliflozin, a novel antihyperglycemic agent.
Chino, Y; Fukasawa, Y; Hachiuma, K; Hasegawa, M; Horiuchi, N; Ishida, M; Nakai, Y; Yamaguchi, J, 2015
)
0.42
" The selected API was ibuprofen sodium dihydrate, a salt of ibuprofen with improved bioavailability and poor intrinsic compactibility."( Improving the granule strength of roller-compacted ibuprofen sodium for hot-melt coating processing.
Becker, K; Garsuch, V; Lopes, DG; Paudel, A; Salar-Behzadi, S; Stehr, M; Zimmer, A, 2016
)
0.43
"In children aged ≤4 years, the relative bioavailability of lamivudine oral solution was 37% lower than that of a tablet formulation."( Effect of Sorbitol on the Pharmacokinetic Profile of Lamivudine Oral Solution in Adults: An Open-Label, Randomized Study.
Adkison, K; Eld, A; Hayward, K; Lou, Y; McCoig, C; Perger, T; Shaefer, M; Vangerow, H; Wolstenholme, A; Zhang, Z, 2018
)
0.48
" Although from a safety perspective the presence of sorbitol in drug formulations does not raise a concern, reports have emerged and these suggest that sorbitol in drug formulations may alter oral absorption and bioavailability of certain drugs."( Use of sorbitol as pharmaceutical excipient in the present day formulations - issues and challenges for drug absorption and bioavailability.
Babu, RJ; Dash, RP; Srinivas, NR, 2019
)
0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" Since the bioavailability of a drug product plays a critical role in the design of oral administration dosage, this study investigated the enzymatic esterification of ibuprofen as a strategy for hydrophilization."( Biocatalytic Approach for Direct Esterification of Ibuprofen with Sorbitol in Biphasic Media.
Costa, S; Rodriguez, MEM; Semeraro, B; Summa, D; Tamburini, E; Zappaterra, F, 2021
)
0.62

Dosage Studied

Repeat dosing of sorbitol during multiple-dose activated charcoal therapy occurred in 33 of 67 (49%) of the EDs surveyed. Parasites synchronized by Sorbitol treatment or refrigeration showed similar dose-response curves and comparable IC50 values to four antimalarial drugs.

ExcerptRelevanceReference
" Differences between oral and parenteral administration are shown and finally dosage guidelines for parenteral administration are established on the basis of the different metabolic effects depending on the administered dose."( [Biochemistry and metabolism of sugar substitutes].
Bässler, KH, 1977
)
0.26
"The utilization of ternary sugar solid dispersion systems and the incorporation of these systems into tablet dosage forms were investigated."( Dissolution rates of hydrocortisone and prednisone utilizing sugar solid dispersion systems in tablet form.
Allen, LV; Levinson, RS; Martono, DD, 1978
)
0.26
"The side effects of high dosed infusions of glucose and glucose substitutes (fructose, sorbitol, xylitol) in metabolically healthy volunteers have been studied."( [Comparison of metabolic effects of infusions of glucose and glucose substitutes].
Förster, H, 1978
)
0.26
" Theoretically one would expect an increase in triglyceride concentration, at least at the high dosed carbohydrate infusions."( [Comparison of side effects of infusion of glucose and glucose substitutes at different doses].
Boecker, S; Förster, H; Zagel, D, 1978
)
0.26
" The intensity of onset and the duration of anticonvulsant activity of the compound were affected depending on th type and form of liquid dosage preparation used."( Vehicle effects on activity of an anticonvulsant compound.
Bloss, J; Sanvordeker, DR, 1977
)
0.26
" Three of the sheep developed further periods of haemolysis after dosing ceased."( Experimental chronic copper toxicity in sheep. Changes that follow the cessation of dosing at the onset of haemolysis.
Gopinath, C; Howell, JM, 1975
)
0.25
" Each group obtained in respect to the part of carbohydrates a different infusion solution (5% glucose, 5% fructose, 5% xylitol, 5% xylitol-glucose-fructose, 5% sorbitol) with an always constant part of electrolytes, the dosage of which was 60 ml/kg body weight on the day of operation and 40 ml/kg body weight during the first 3 postoperative days being continuously distributed over 24 hours."( [Metabolic behavior and utilization of parenterally administered carbohydrates in the postoperative phase].
Ahnefeld, FW; Dölp, R; Grab, E; Knoche, E, 1975
)
0.25
" The precise dosage of trace elements like zinc or magnesium is unknown."( [Recommendations for the use of carbohydrates in the infusion therapy].
Berg, G, 1975
)
0.25
" Rate constants of transport between the compartments investigated were determined; they showed characteristics which could be related to the substance and the dosage administered."( Gastrointestinal transit and digestibility of maltitol, sucrose and sorbitol in rats: a multicompartmental model and recovery study.
Grossklaus, R; Herold, M; Klingebiel, L; Krüger, D; Lorenz, S, 1992
)
0.28
" Despite the poor suspension of charcoal in sorbitol and the less than ideal conditions under which it is given, the patient receives an adequate dosage of AC if it is ordered."( Container residue after activated charcoal administration in the emergency department.
Harchelroad, F, 1992
)
0.28
"The present study was carried out to investigate the time course of metabolization in brain and the influence on RNA synthesis of a retention-improving dosage of methylglucamine orotate after intracerebroventricular application."( Metabolization of a retention-improving dosage of methylglucamine orotate in rat brain.
Matthies, H; Popov, N; Staak, S; Tischmeyer, W, 1990
)
0.28
" The three ARIs (AL01567, AL01576, and AL01750) were administered intravenously as a single dose to all species except rat, which was dosed orally with AL01750, and man, who was dosed orally with AL01567 and AL01576."( Interspecies comparison of the pharmacokinetics of aldose reductase inhibitors.
Barker, R; Brazzell, RK; Couch, R; McCue, B; Park, YH; Wooldridge, CB; York, B,
)
0.13
" Based on our experience with this case, several recommendations are provided regarding management of drug intoxications with charcoal-sorbitol suspension, including meticulous attention to fluid-electrolyte balance, type of replacement fluid, and dosing of the suspension."( Hypernatremia due to repeated doses of charcoal-sorbitol.
Allerton, JP; Strom, JA, 1991
)
0.28
"A number of dosing regimens was assessed to determine the optimum schedule of administration of N-(4-methoxybenzyl)-N-dithiocarboxy-D-glucamine (MeOBDCG) in depleting whole-body, renal and hepatic levels of metallothionein-bound cadmium (Cd) in mice."( Schedule dependency of a cadmium-complexing dithiocarbamate analog in mice.
Atkins, LM; Gale, GR; Jones, MM; Singh, PK; Smith, AB, 1990
)
0.28
" Though a prospective, controlled study needs to be performed, variation in dosage of the CSS may be appropriate in select patient groups to offset the effects of the ingestant on bowel motility."( Gastrointestinal transit times of a charcoal/sorbitol slurry in overdose patients.
Cottington, E; Harchelroad, F; Krenzelok, EP, 1989
)
0.28
" A dose-response study was made of the mobilization of cadmium from the liver and kidney of cadmium-loaded mice by NaB; this showed that NaB is one of the most effective cadmium mobilizing agents developed to date."( Meso-2,3-dimercaptosuccinic acid and sodium N-benzyl-N-dithiocarboxy-D-glucamine as antagonists for cadmium intoxication.
Basinger, MA; Gale, GR; Holscher, MA; Jones, MM; Jones, SG; Topping, RJ, 1988
)
0.27
" An examination of the dose-response curve for the suppression of cis-platinum nephrotoxicity by NaG shows that this can be achieved with mole ratios of NaG: cis-platinum as low as 1:1 given after appropriate pretreatment."( Control of some aspects of cis-platinum nephrotoxicity.
Basinger, MA; Craft, WD; Domingo, JL; Jones, MM; Llobet, JM, 1986
)
0.27
"Two new potent aldose reductase inhibitors, AL-1567 (DL-spiro(2-fluoro-9H-fluoren-9,4'-imidazolidine)-2',5'-dione) and AL-1576 (spiro-(2,7-difluoro-9H-fluoren-9,4'-imidazolidine)2',5'-dione), have been characterized with respect to in vitro activity toward rat lens and human placental aldose reductase and in vivo activity in uncontrolled, severely diabetic rats dosed acutely with the compounds."( Effects of two new aldose reductase inhibitors, AL-1567 and AL-1576, in diabetic rats.
Chandler, ML; Griffin, BW; McNatt, LG; York, BM, 1987
)
0.27
" Side-effects are usually not to be expected if indications and dosage are carefully determined."( [Fructose and sorbitol as energy-supplying substrates for parenteral nutrition].
Förster, H, 1987
)
0.27
" In addition, 65% xylitol chewing-gum produced better results than did that containing 15% xylitol, suggesting a dose-response relationship."( Clinical results after 12 months from a study of the incidence and progression of dental caries in relation to consumption of chewing-gum containing xylitol in school preventive programs.
Gagnon, G; Kandelman, D, 1987
)
0.27
" Due to its longer efficacy, glycerol provides an important supplement or alternative to sorbitol therapy, especially as the permitted maximum dosage would have to have been exceeded in a treatment consisting exclusively of sorbitol."( [Intracranial pressure-controlled treatment of brain edema with glycerin and sorbitol in intracerebral hemorrhage].
Brenner, M; Haass, A; Hamann, G; Harms, M; Kloss, R; Schimrigk, K, 1987
)
0.27
"The role of the increased hepatocellular redox-state [( NADH]/[NAD+] ratio) as a mechanism underlying hepatic triglyceride deposition after acute ethanol dosing has been investigated in the rat."( The role of the hepatocellular redox state in the hepatic triglyceride accumulation following acute ethanol administration.
Chakraborty, J; Ryle, PR; Thomson, AD, 1986
)
0.27
" EB 51 was administered in 43 patients during several days at a dosage of 1000 or 1500 ml."( [EB 51 (Trivemil), a complete nutriment for parenteral alimentation].
Becker, H; Crastes de Paulet, A; Crastes de Paulet, P; du Cailar, J; Kienlen, J; Magnan de Bornier, B, 1974
)
0.25
" In the retinas of controls, dosage with ICI 105552 reduced the concentration of sorbitol by 36% without other effects."( The effects of an aldose reductase inhibitor upon the sorbitol pathway, fructose-1-phosphate and lactate in the retina and nerve of streptozotocin-diabetic rats.
Earl, DC; Heath, H; Mirrlees, DJ; Poulsom, R, 1983
)
0.27
"To test the possible involvement of the sorbitol pathway in the pathogenesis of retinopathy in long-term experimentally-diabetic rats, streptozotocin-diabetic and normal rats were dosed orally (50 mg/kg body weight daily) for up to 373 days with an aldose reductase inhibitor (ICI 105552) or a placebo."( The effects of long-term treatment of streptozotocin-diabetic rats with an aldose reductase inhibitor.
Boot-Handford, RP; Heath, H; Poulsom, R, 1983
)
0.27
" High dietary concentrations of lactose give rise to a similar spectrum of effects when given in excessive dosage to laboratory rats."( Perspectives in carbohydrate toxicology with special reference to carcinogenicity.
Roe, FJ, 1984
)
0.27
" In diabetic rats with severe hyperglycemia, oral sorbinil (5 mg/kg) dramatically reduced (80-90%) sorbitol levels in tissues without affecting blood glucose; the RBC dose-response curve was similar to that in lens and sciatic nerve."( Red blood cell sorbitol as an indicator of polyol pathway activity. Inhibition by sorbinil in insulin-dependent diabetic subjects.
Aldinger, CE; Leavengood, H; Malone, JI; O'Brien, MM; Page, MG; Peterson, MJ, 1984
)
0.27
" It is concluded, that different guidelines for the dosage of intravenous fat should be given."( [Differences in the elimination of intravenously administered intralipid and lipofundin S].
Förster, H, 1981
)
0.26
"Absorption, distribution and excretion of 14C-D-glucitol hexanicotinate (sorbinicate, SN) were studied after oral dosing in the rat against 14C-nicotinic acid (NA)."( On the absorption, distribution and excretion of sorbinicate in the rat and the monkey.
Bramanti, G; Criscuoli, M; Giachetti, C; Mondino, A; Silvestri, S; Subissi, A; Zanolo, G, 1982
)
0.26
" Sorbitol at a dosage of 20 g did not act as a laxative, produced the smallest BG increase, and required the least amount of insulin to return to baseline."( [A comparison of the blood glucose increase and insulin requirement after oral sucrose, fructose and sorbitol alone or in combination (author's transl)].
Irsigler, K; Kaspar, L, 1980
)
0.26
" This may have important implications for drug dosage in patients in an intensive care unit (ICU)."( Rapid determination of functional liver plasma flow in ICU patients by a modified hepatic D-sorbitol plasma clearance method.
Köppel, C; Müller, C; Pohle, S,
)
0.13
"Certain sugar alcohols, notably sorbitol, are widely used as a vehicle for drugs in liquid oral dosage forms."( Gastrointestinal effects of sorbitol as an additive in liquid medications.
Andritz, MH; Govel, LA; Johnston, KR, 1994
)
0.29
" Repeat dosing of sorbitol during multiple-dose activated charcoal therapy occurred in 33 of 67 (49%) of the EDs surveyed."( Prevalence of sorbitol in multiple-dose activated charcoal regimens in emergency departments.
Goldfrank, LR; Hoffman, RS; Howland, MA; Mercurio, M; Wang, RY; Wax, PM, 1993
)
0.29
"Sorbitol dosing is often repeated with activated charcoal during multiple-dose activated charcoal therapy in the ED because of the ready availability (and sometimes exclusive availability) of premixed activated charcoal in sorbitol preparations."( Prevalence of sorbitol in multiple-dose activated charcoal regimens in emergency departments.
Goldfrank, LR; Hoffman, RS; Howland, MA; Mercurio, M; Wang, RY; Wax, PM, 1993
)
0.29
" ruminantium SS2/R5 failed to establish in sheep which were dosed twice daily with 10 g of sorbitol."( Isolation and attempted introduction of sugar alcohol-utilizing bacteria in the sheep rumen.
Walker, ND; Wallace, RJ, 1993
)
0.29
" Compared to BGDTC, the new compounds were, except at the highest dosage studied, equally or more effective in decreasing retention of hepatic cadmium, while mostly less effective in decreasing renal cadmium."( Meso-2,3-dimercaptosuccinic acid mono-N-alkylamides: syntheses and biological activity as novel in vivo cadmium mobilizing agents.
Blanusa, M; Jones, MM; Piasek, M; Restek-Samarzija, N; Rostial, K; Singh, PK, 1996
)
0.29
" The location of a tube in the gastrointestinal tract, as well as the problems involved in crushing and administering solid dosage forms, creates a unique set of problems."( Drug-nutrient interactions in enteral feeding: a primary care focus.
Jones, E; Meguid, MM; Varella, L, 1997
)
0.3
" Adequate intravenous iron supplementation allows reduction of epoetin dosage by approximately 40%."( Safety aspects of parenteral iron in patients with end-stage renal disease.
Hörl, WH; Sunder-Plassmann, G, 1997
)
0.3
" One of these toxic findings was cataract, and we have found that cataract appeared in rats dosed orally with FK506 for 13 weeks and more."( Cataract development induced by repeated oral dosing with FK506 (tacrolimus) in adult rats.
Fukuhara, Y; Hisatomi, A; Ishida, H; Mitamura, T; Murato, K; Ohara, K; Takahashi, Y, 1997
)
0.3
" Surface acidities of common excipients used in preparation of solid dosage forms are presented."( Surface acidity of solid pharmaceutical excipients III. Excipients for solid dosage forms.
Oelkrug, D; Scheef, CA; Schmidt, PC, 1998
)
0.3
" Only free sorbitol was detected in the gastrointestinal contents in both dosage groups."( Small intestinal transit and digestibility of lactitol in Wistar rats.
Grossklaus, R; Krüger, D; Soontornchai, S, 1998
)
0.3
" A case-control study showed a dose-response relationship between sausage consumption and illness."( A large outbreak of hemolytic uremic syndrome caused by an unusual sorbitol-fermenting strain of Escherichia coli O157:H-.
Ammon, A; Karch, H; Petersen, LR, 1999
)
0.3
"When either grape or pear juice is administered in a dosage of 10 mL/kg/day, the carbohydrate is well absorbed, produces no adverse gastrointestinal symptoms, and has no effect on stool water in healthy infants."( Carbohydrate absorption from fruit juices in infants.
Lifschitz, CH, 2000
)
0.31
" Pkc1p, the yeast protein kinase C homolog which is thought to regulate the Mpk1p MAP kinase pathway involved in cell wall remodelling and polarized cell growth, was found to act as a dosage suppressor of glc7-10."( Type 1 protein phosphatase is required for maintenance of cell wall integrity, morphogenesis and cell cycle progression in Saccharomyces cerevisiae.
Andrews, PD; Stark, MJ, 2000
)
0.31
"We carried out a randomized, double-blind, crossover study of 85 women, designed to investigate the dose-response of daily Mg supplementation on premenstrual symptoms."( Unexpected benefit of sorbitol placebo in Mg intervention study of premenstrual symptoms: implications for choice of placebo in RCTs.
Bolland, KM; De Souza, MC; Marakis, G; Morris, AP; Robinson, PA; Walker, AF, 2002
)
0.31
" The development of various dosage forms of sCT, especially solid dosage forms, appears be feasible using proliposomes."( Preparation and evaluation of proliposomes containing salmon calcitonin.
Chung, SJ; Shim, CK; Song, KH, 2002
)
0.31
"For patients with attention-deficit/hyperactivity disorder who have hepatic impairment, dosage adjustment is recommended."( Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites.
Chalon, SA; Desager, JP; Desante, KA; Frye, RF; Golnez, JL; Horsmans, Y; Long, AJ; Sauer, JM; Smith, BP; Thomasson, HR; Witcher, J, 2003
)
0.32
"The objective of this study was to prepare novel capsule-based fast disintegrating dosage forms for the oral cavity (Fastcaps)."( Preparation and characterization of novel fast disintegrating capsules (Fastcaps) for administration in the oral cavity.
Bodmeier, R; Ciper, M, 2005
)
0.33
"DM2 patients were dosed with losartan (100 mg/d) and urines were collected at week 8 and 12."( [Assessment of therapeutic effect of losartan on diabetes mellitus with gas chromatography-based metabonomics].
Gao, P; Lu, X; Shi, XZ; Xu, GW; Yuan, KL, 2007
)
0.34
" Unfolding of enzyme structures and disruption of secondary and three-dimensional structures occurred when the exposed PEF dosage exceeds a critical value, which caused the decrease in activity."( Protective effect of sorbitol on enzymes exposed to microsecond pulsed electric field.
Yang, R; Zhao, W, 2008
)
0.35
"Although research gaps exist, particularly on optimal dosing and relative polyol efficacy, research evidence supports using polyol-containing chewing gum as part of normal oral hygiene to prevent dental caries."( The impact of polyol-containing chewing gums on dental caries: a systematic review of original randomized controlled trials and observational studies.
Deshpande, A; Jadad, AR, 2008
)
0.35
" Therefore, we recommend preparing the tablets with XYL or SOR as a binder using the wet granule compression method to produce a compact dosage form of MC."( Preparation and evaluation of medicinal carbon tablets with different saccharides as binders.
Ito, A; Machida, Y; Yamamoto, K, 2009
)
0.35
"The present study was aimed at developing a soft chewable dosage form for calcium carbonate for nutraceutical application."( Investigation of organoleptic characteristics in the development of soft chews of calcium carbonate as mineral supplement.
Mishra, B; Sharma, G; Shukla, D, 2009
)
0.35
" Single oral dosing studies were performed in rats, mice and dogs to assess the abilities of TS-071 to increase urinary glucose excretion and to lower plasma glucose levels."( TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity.
Arai, M; Asami, J; Fukuhara, N; Gunji, E; Kitano, K; Kojima, N; Kozakai, A; Okumura-Kitajima, L; Takahashi, K; Takahashi, T; Tomoike, H; Toyoda, H; Uchida, S; Yamamoto, K, 2011
)
0.37
" Nebulization of mannitol by vibrating mesh devices has recently been shown in vitro to impart similar dosing in a comparable or lesser treatment time."( Delivery of high solubility polyols by vibrating mesh nebulizer to enhance mucociliary clearance.
Chan, HK; Chan, JG; Kwok, PC; Traini, D; Young, PM, 2012
)
0.38
" Parasites synchronized by sorbitol treatment or refrigeration showed similar dose-response curves and comparable IC50 values to four antimalarial drugs."( Refrigeration provides a simple means to synchronize in vitro cultures of Plasmodium falciparum.
Cui, L; Feng, G; Hao, M; He, Y; Li, X; Rosenthal, BM; Sun, L; Wu, L; Xiang, Z; Yang, Z; Yuan, L; Zhao, Z, 2014
)
0.4
" These include the question as to when and to whom early use of SGLT2 inhibitors would be most suitable, as well as instructions on reduction of sulfonylurea dosage during add-on treatment."( Luseogliflozin and other sodium-glucose cotransporter 2 inhibitors: no enemy but time?
Pafili, K; Papanas, N, 2015
)
0.42
" The pharmacokinetic and pharmacodynamic profile of luseogliflozin observed in this study supports its once-daily dosing regimen."( Pharmacokinetics, Pharmacodynamics, and Safety of Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized, Single-blind, Placebo-controlled Trial.
Fukatsu, A; Sakai, S; Samukawa, Y; Sasaki, T; Seino, Y; Ubukata, M, 2015
)
0.42
" Dose-response curves of responses induced by acetylcholine, the calcium ionophore A23187, and sodium nitroprusside were generated using isolated rat aorta with or without LE."( Lipid Emulsion Attenuates Acetylcholine-Induced Relaxation in Isolated Rat Aorta.
Baik, J; Cho, H; Choi, MJ; Chung, YK; Han, JY; Hong, JM; Lee, HK; Lee, SH; Lee, Y; Ok, SH; Park, J; Shin, IW; Sohn, JT; Yu, J, 2015
)
0.42
" The versatility of this method was demonstrated by different examples, including the excipients mixture and commercial solid dosage forms (e."( Application of
Pisklak, DM; Szeleszczuk, Ł; Zielińska-Pisklak, M, 2016
)
0.43
"Medicated jelly formulations are patient friendly dosage form for pediatric, geriatric and dysphagic patients."( Formulation, Evaluation and release rate characteristics of medicated jelly of vitamin C.
Abd El-Salam, NM; Husain, T; Ibrahim, KA; Iqbal, FM; Khan, A; Mumtaz, S; Nawaz, A; Shah, SNH; Ullah, N; Zaman, S, 2017
)
0.46
" A novel polytherapeutic proof-of-principle approach using PXT3003, a low-dose combination of baclofen, naltrexone and sorbitol, slowed disease progression after long-term dosing in adult Pmp22 transgenic rats, a known animal model of CMT1A."( Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A (CMT1A).
Adam, J; Cohen, D; Ewers, D; Hajj, R; Kungl, T; Mroczek, M; Nabirotchkin, S; Nave, KA; Prukop, T; Sereda, MW; Stenzel, J; Wernick, S, 2019
)
0.51
"Lipids were dosed up to 3 g/kg/day and reduced as enteral nutrition progressed."( Head Circumference Growth Is Enhanced by SMOFlipid in Preterm Neonates.
Bin-Nun, A; Hammerman, C; Kassirer, Y; Mimouni, FB; Shchors, I, 2020
)
0.56
" The main objective of this study is to develop a patient complaint tablet dosage form which is sugar free, chewable and easy to use."( Formulation development of sugar free antacid chewable tablets for diabetes induced acidity in patients.
Ayaz, S; Khan, M; Naveed, S; Owais, A; Qamar, F; Rehman, H; Sana, A, 2019
)
0.51
" The primary objective was to examine the dose-response relationship of licogliflozin treatment in body weight reduction relative to placebo at 12 weeks."( Dose-dependent reduction in body weight with LIK066 (licogliflozin) treatment in Japanese patients with obesity.
Keefe, D; Sano, M; Tsumiyama, I; Yokote, K, 2020
)
0.56
"This dose-response analysis evaluated change in body weight following 24 weeks with four once-daily and twice-daily licogliflozin doses (2."( Licogliflozin, a Novel SGLT1 and 2 Inhibitor: Body Weight Effects in a Randomized Trial in Adults with Overweight or Obesity.
Bays, HE; Keefe, D; Kozlovski, P; Proot, P; Shao, Q, 2020
)
0.56
"Licogliflozin once daily or twice daily produced a significant dose-response signal for weight loss versus placebo (P < 0."( Licogliflozin, a Novel SGLT1 and 2 Inhibitor: Body Weight Effects in a Randomized Trial in Adults with Overweight or Obesity.
Bays, HE; Keefe, D; Kozlovski, P; Proot, P; Shao, Q, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (936 Items)

ItemProcessFrequency
Snackscore-ingredient2,530
Sweet snackscore-ingredient2,019
Confectioneriescore-ingredient1,843
sucréscore-ingredient384
Confiseriescore-ingredient276
Chewing-gumcore-ingredient195
Dessertscore-ingredient193
Frozen foodscore-ingredient180
Cocoa and its productscore-ingredient176
Chocolate candiescore-ingredient175
Chewing gumcore-ingredient164
Biscuits and cakescore-ingredient164
Candiescore-ingredient159
Chewing-gum sans sucrescore-ingredient153
Sugar-free chewing gumcore-ingredient138
Mealscore-ingredient135
Seafoodcore-ingredient133
Frozen dessertscore-ingredient129
Biscuits et gâteauxcore-ingredient121
Snacks dulcescore-ingredient102
Botanascore-ingredient102
Plant-based foods and beveragescore-ingredient93
Gâteauxcore-ingredient93
Biscuitscore-ingredient91
Sushiscore-ingredient82
Sushis-and-makiscore-ingredient81
Plant-based foodscore-ingredient77
Cakescore-ingredient76
Gummi candiescore-ingredient69
Dulcescore-ingredient61
Bonbonscore-ingredient57
Condimentscore-ingredient48
Meats and their productscore-ingredient48
Meatscore-ingredient47
Gummy bearscore-ingredient45
Saladscore-ingredient44
Prepared saladscore-ingredient44
Prepared meatscore-ingredient44
Saucescore-ingredient41
Syrupscore-ingredient39
Sausagescore-ingredient39
en:open-beauty-factscore-ingredient38
Simple syrupscore-ingredient37
Sweetenerscore-ingredient37
Groceriescore-ingredient34
Beveragescore-ingredient34
Canned foodscore-ingredient33
Open Beauty Factscore-ingredient33
Snacks sucréscore-ingredient31
Fruits and vegetables based foodscore-ingredient30
Canned plant-based foodscore-ingredient29
Fruits based foodscore-ingredient28
Galletas y pastelescore-ingredient28
Canned fruitscore-ingredient27
Dietary supplementscore-ingredient27
Pâtisseriescore-ingredient27
Chiclescore-ingredient26
Madeleinescore-ingredient26
Chicles sin azúcarcore-ingredient25
Alimentos y bebidas de origen vegetalcore-ingredient25
en:confectioneriescore-ingredient25
Baking decorationscore-ingredient25
Non food productscore-ingredient22
Cacao et dérivéscore-ingredient22
Licensed productscore-ingredient21
Frozen seafoodcore-ingredient20
Desayunoscore-ingredient20
Alimentos de origen vegetalcore-ingredient20
Cereals and potatoescore-ingredient20
Aliments et boissons à base de végétauxcore-ingredient19
Untablescore-ingredient19
Gâteaux au chocolatcore-ingredient19
Aliments d'origine végétalecore-ingredient18
Breakfastscore-ingredient18
Untables dulcescore-ingredient18
Ice creamscore-ingredient17
Ice creams and sorbetscore-ingredient17
Bebidascore-ingredient17
Specific productscore-ingredient17
Bodybuilding supplementscore-ingredient17
Tartes sucréescore-ingredient17
en:Sweet snackscore-ingredient17
Pastelescore-ingredient17
Barscore-ingredient16
Spreadscore-ingredient16
Productos a base de carnecore-ingredient16
Tartescore-ingredient16
en:candiescore-ingredient15
Plant-based beveragescore-ingredient15
Sweet spreadscore-ingredient15
Plant-based spreadscore-ingredient15
Mochicore-ingredient15
Dulces de Navidadcore-ingredient15
Gastronomía navideñacore-ingredient15
Alimentos festivoscore-ingredient15
Chocolatescore-ingredient14
Fruit and vegetable preservescore-ingredient14
Protein barscore-ingredient14
Embutidoscore-ingredient14
Carnescore-ingredient14
en:Snackscore-ingredient14
en:sugar-free-chewing-gumcore-ingredient14
Barritascore-ingredient13
Salted snackscore-ingredient13
Bebidas azucaradascore-ingredient13
Dipscore-ingredient13
Compléments alimentairescore-ingredient13
Aliments festifscore-ingredient13
Turronescore-ingredient13
Pastriescore-ingredient12
Dairiescore-ingredient12
Cereals and their productscore-ingredient12
Aliments et boissons de Noëlcore-ingredient12
Fermented foodscore-ingredient11
Bonbons de chocolatcore-ingredient11
Confiseries chocolatéescore-ingredient11
Preparaciones a base de frutas y verdurascore-ingredient11
Untables vegetalescore-ingredient11
Chocolatscore-ingredient11
Surgeléscore-ingredient11
Confiseries de Noëlcore-ingredient11
Fermented milk productscore-ingredient10
Dried products to be rehydratedcore-ingredient10
Dried productscore-ingredient10
Cooking helperscore-ingredient10
Confituracore-ingredient10
Golosinascore-ingredient10
en:Chewing gumcore-ingredient10
endulzadas artificialmentecore-ingredient9
Fruitscore-ingredient9
Dehydrated beveragescore-ingredient9
Surimicore-ingredient9
en:groceriescore-ingredient9
Barritas de cerealescore-ingredient9
Tartelettescore-ingredient9
Jamón cocido de cerdocore-ingredient9
Ice cream sandwichescore-ingredient8
Chocolate cakescore-ingredient8
Fishescore-ingredient8
Maple syrupscore-ingredient8
Breadscore-ingredient8
Macaronscore-ingredient8
Marshmallows coated with chocolatecore-ingredient8
Toothpastecore-ingredient8
Sweetened beveragescore-ingredient8
Muffinscore-ingredient8
en:cakescore-ingredient8
Touroncore-ingredient8
Turrones de almendrascore-ingredient8
Browniescore-ingredient7
Cereal barscore-ingredient7
Produits de la mercore-ingredient7
Cake mixescore-ingredient7
Dessert mixescore-ingredient7
Baking Mixescore-ingredient7
Pastry helperscore-ingredient7
Pâtes au wasabicore-ingredient7
Jamscore-ingredient7
Tartes à la crèmecore-ingredient7
Quatre-quartscore-ingredient7
Fruits et produits dérivéscore-ingredient7
Aliments à base de fruits et de légumescore-ingredient7
en:Sugar-free chewing gumcore-ingredient7
en:Products for specific dietscore-ingredient7
en:Specific productscore-ingredient7
Bizcochocore-ingredient7
Sodascore-ingredient6
Cheesescore-ingredient6
Acid gummy candiescore-ingredient6
Fatscore-ingredient6
Fish preparationscore-ingredient6
Jamón cocidocore-ingredient6
Jamóncore-ingredient6
Productos sin glutencore-ingredient6
Non alimentairecore-ingredient6
Galletascore-ingredient6
Plats préparéscore-ingredient6
Produits déshydratéscore-ingredient6
Pan dulcecore-ingredient6
Magdalenascore-ingredient6
Fruit-based beveragescore-ingredient6
fr:Charcuteries cuitescore-ingredient6
Dark chocolatescore-ingredient5
Marshmallowscore-ingredient5
Vitaminscore-ingredient5
Bebidas a base de frutascore-ingredient5
Bebidas de origen vegetalcore-ingredient5
Carbonated drinkscore-ingredient5
Barrescore-ingredient5
Gumcore-ingredient5
Suplementos dietéticoscore-ingredient5
Chocolats au laitcore-ingredient5
en:biscuitscore-ingredient5
Madeleines naturescore-ingredient5
Chewing-gum sucrécore-ingredient5
Boissonscore-ingredient5
Aliments à base de plantes séchéescore-ingredient5
Terrinescore-ingredient5
Cacao y sus productoscore-ingredient5
Zoetwarencore-ingredient5
Zoete snackscore-ingredient5
en:cooked-poultry-breast-slicescore-ingredient5
en:chewing-gumcore-ingredient4
Céréales et pommes de terrecore-ingredient4
Bars covered with chocolatecore-ingredient4
Yogurtscore-ingredient4
Fermented dairy dessertscore-ingredient4
Dairy dessertscore-ingredient4
Stuffed waferscore-ingredient4
Waferscore-ingredient4
Lácteoscore-ingredient4
Mermeladas y confituras dietéticascore-ingredient4
Bonbons gélifiéscore-ingredient4
Chocolats fourréscore-ingredient4
Dulce de lechecore-ingredient4
Süßer Snackcore-ingredient4
Imbisscore-ingredient4
en:pastriescore-ingredient4
Vitaminescore-ingredient4
Pâtes d'amandecore-ingredient4
Massepaincore-ingredient4
Fruits secscore-ingredient4
saléscore-ingredient4
Sauces dessertcore-ingredient4
Bonbons durscore-ingredient4
Gumă de mestecatcore-ingredient4
dulcicore-ingredient4
Gustăricore-ingredient4
en:Biscuits and cakescore-ingredient4
Lanches docescore-ingredient4
Lanches comidacore-ingredient4
Caramelos de gomacore-ingredient4
Bonbons dragéifiéscore-ingredient4
Suikervrije kauwgomcore-ingredient4
Kauwgomcore-ingredient4
Turrones blandos de almendrascore-ingredient4
Sliced breadscore-ingredient4
Cereales y patatascore-ingredient3
Mandarin orangescore-ingredient3
Citruscore-ingredient3
Amuse-gueulescore-ingredient3
Nuts and their productscore-ingredient3
Gummi Worms Fruitcore-ingredient3
Gummi Wormscore-ingredient3
Sandwichescore-ingredient3
Ice cream barscore-ingredient3
Chocolate trufflescore-ingredient3
Endulzantescore-ingredient3
Fishes and their productscore-ingredient3
Protein Energy Barscore-ingredient3
en:frozen-dessertscore-ingredient3
Préparations de poissoncore-ingredient3
Poissons et dérivéscore-ingredient3
Poissonscore-ingredient3
Caramelscore-ingredient3
Vanilla stuffed waferscore-ingredient3
Wasabi pastescore-ingredient3
Vitaminascore-ingredient3
Tea-based beveragescore-ingredient3
Hot beveragescore-ingredient3
Fruits à coques et dérivéscore-ingredient3
Mintcore-ingredient3
Aromatic plantscore-ingredient3
Culinary plantscore-ingredient3
Barras de Cerealcore-ingredient3
Zuckerfreie Kaugummiscore-ingredient3
Kaugummiscore-ingredient3
Süßwarencore-ingredient3
Biscuits secscore-ingredient3
Gâteaux marbréscore-ingredient3
Tartelettes à la préparation de fruitscore-ingredient3
Dattes Deglet Nourcore-ingredient3
Dattescore-ingredient3
de poissoncore-ingredient3
Glaces et sorbetscore-ingredient3
Desserts glacéscore-ingredient3
Assortiments de bonbons de chocolatcore-ingredient3
Chocolats noirscore-ingredient3
Viandescore-ingredient3
Viandes et dérivéscore-ingredient3
Coulis de fruitscore-ingredient3
Non-Food-Produktecore-ingredient3
Bolleriacore-ingredient3
Postrescore-ingredient3
en:Dessertscore-ingredient3
Wafflescore-ingredient3
Guimauvescore-ingredient3
Sobremesascore-ingredient3
Génoises en tranches fourréescore-ingredient3
Donutscore-ingredient3
Crostatinacore-ingredient3
Artificially sweetened beveragescore-ingredient3
Barritas de frutos de cáscaracore-ingredient3
Frutos de cáscara y derivadoscore-ingredient3
Carameloscore-ingredient3
Confeitariacore-ingredient3
Productos del marcore-ingredient3
Conservascore-ingredient3
Dulces de chocolatecore-ingredient3
Still fruit soft drink with sugarcore-ingredient3
Still fruit soft drinkscore-ingredient3
Dolcicore-ingredient3
Turrones duros de almendrascore-ingredient3
Fiambre de pechuga de pavocore-ingredient3
Avescore-ingredient3
Chocolate cereal barscore-ingredient2
Peaches in syrupcore-ingredient2
Peachescore-ingredient2
Fruits in syrupcore-ingredient2
Tomato saucescore-ingredient2
Snacks saléscore-ingredient2
Assorted chocolatescore-ingredient2
Caramel chocolate barscore-ingredient2
Gummy candycore-ingredient2
Jelly beanscore-ingredient2
Roasted peanutscore-ingredient2
Peanutscore-ingredient2
Roasted nutscore-ingredient2
Nutscore-ingredient2
Legumescore-ingredient2
Legumes and their productscore-ingredient2
en:Concentrate syrup without sugar and with artificial sweetenerscore-ingredient2
en:Sugar-free flavoured syrupscore-ingredient2
Siropes aromatizadoscore-ingredient2
Siropescore-ingredient2
Festive foodscore-ingredient2
Plant-based picklescore-ingredient2
Vegetables based foodscore-ingredient2
Picklescore-ingredient2
Pastascore-ingredient2
Canned meatscore-ingredient2
Hard candiescore-ingredient2
Fruits à coquescore-ingredient2
Aromatic-herbscore-ingredient2
Chocolats au lait fourréscore-ingredient2
Dark chocolate with caramelcore-ingredient2
Caramel chocolatescore-ingredient2
Édulcorantscore-ingredient2
Mexican Dinner Mixescore-ingredient2
Energy barscore-ingredient2
Ice cream tubscore-ingredient2
Frozen meatscore-ingredient2
Meat alternativescore-ingredient2
Hotpotscore-ingredient2
en:Sausagescore-ingredient2
en:Prepared meatscore-ingredient2
en:Meatscore-ingredient2
en:Meats and their productscore-ingredient2
Confiseries de Francecore-ingredient2
Eucalyptuscore-ingredient2
Herbal teascore-ingredient2
Painscore-ingredient2
Tartes aux fruitscore-ingredient2
Tartes aux pommescore-ingredient2
Kouign-amanncore-ingredient2
Fresh foodscore-ingredient2
Terrines de saumoncore-ingredient2
Sorbetscore-ingredient2
Madeleines au chocolatcore-ingredient2
Chocolats noirs fourréscore-ingredient2
Petit-déjeunerscore-ingredient2
Plats au porccore-ingredient2
Brochettes de viandecore-ingredient2
Brochettescore-ingredient2
Porccore-ingredient2
Préparations de viandecore-ingredient2
Plats préparés à la viandecore-ingredient2
Porc et dérivéscore-ingredient2
Canistrellicore-ingredient2
Muffins au chocolatcore-ingredient2
Friandisecore-ingredient2
Financierscore-ingredient2
Coulis de framboisecore-ingredient2
Medizinproduktcore-ingredient2
Bezcukrowa guma do żuciacore-ingredient2
Guma do żuciacore-ingredient2
Słodkie przekąskicore-ingredient2
Przekąskicore-ingredient2
Gumă de mestecat fără zahărcore-ingredient2
Сладки закускиcore-ingredient2
Закускиcore-ingredient2
Bonbons à la menthecore-ingredient2
Sladké svačinycore-ingredient2
Svačinycore-ingredient2
Soupscore-ingredient2
Jaffa cakescore-ingredient2
en:Sponge cake filled and covered with chocolatecore-ingredient2
en:sponge-cakecore-ingredient2
Kakecore-ingredient2
Tartelettes aux fruits entiers ou coupéscore-ingredient2
Filled biscuitscore-ingredient2
Viennoiseriescore-ingredient2
Chocolate madeleinescore-ingredient2
Mermeladas y confituras de melocotóncore-ingredient2
es:Pan dulcecore-ingredient2
es:Pastelitoscore-ingredient2
Bebidas endulzadas artificialmentecore-ingredient2
Barras rellenascore-ingredient2
Chewing-gum à la menthecore-ingredient2
Grickalicecore-ingredient2
en:Soft caramel candycore-ingredient2
en:Flavoured milk chocolatescore-ingredient2
en:Flavoured chocolatescore-ingredient2
Chocolates con lechecore-ingredient2
Chocolates con edulcorantescore-ingredient2
Alfajorescore-ingredient2
Mermeladas y confituras de frutas del bosquecore-ingredient2
Suplementos de culturismocore-ingredient2
Barritas de chocolatecore-ingredient2
Alimentos à base de plantascore-ingredient2
Alimentos e bebidas à base de plantascore-ingredient2
Presuntoscore-ingredient2
Carnes preparadascore-ingredient2
Produtos à base de carnecore-ingredient2
Snackcore-ingredient2
en:Snacks sucréscore-ingredient2
en:Confiseriescore-ingredient2
Fraiscore-ingredient2
Tourons aux amandescore-ingredient2
Turrones de cococore-ingredient2
Turrones de nata y nuecescore-ingredient2
Turrón aux fruitscore-ingredient2
Calamarescore-ingredient2
Moluscocore-ingredient2
Frutascore-ingredient2
Frutas y sus productoscore-ingredient2
Frutas y verduras y sus productoscore-ingredient2
Fiambre de pechuga de pollocore-ingredient2
Pavocore-ingredient2
Pavo y sus productoscore-ingredient2
Jamón cocido de pavocore-ingredient2
Pechuga de pollo cocidacore-ingredient2
Productos no alimenticioscore-ingredient2
Lemon soft drinkscore-ingredient2
Fruit sodascore-ingredient2
Still soft drink with tea extract with sugar and artificial sweetener(core-ingredient2
Still soft drink with tea extractcore-ingredient2
Fast-foodcore-ingredient2
Snacks Snacks sucrés Confiseriescore-ingredient1
en:chocolate-candiescore-ingredient1
Fiber one chocolate fudge browniecore-ingredient1
Chocolate-high-fiber-browniecore-ingredient1
Cereales para el desayunocore-ingredient1
Cereales y derivadoscore-ingredient1
en:Digestive medicinecore-ingredient1
Lebensmittelfarbecore-ingredient1
Lebensmittelzusatzstoffcore-ingredient1
Sodas a base de frutascore-ingredient1
Bebidas carbonatadascore-ingredient1
Bebidas no alcohólicascore-ingredient1
Shortbread cookiescore-ingredient1
Sushi and Makicore-ingredient1
Tilapiacore-ingredient1
Pasta saucescore-ingredient1
Chips de pommes de terrecore-ingredient1
Chipscore-ingredient1
Chips et fritescore-ingredient1
Orange-marmaladescore-ingredient1
Marmaladescore-ingredient1
Peanut barscore-ingredient1
Nut barscore-ingredient1
en:frozen-seafoodcore-ingredient1
Siropes simplescore-ingredient1
Mayonnaisescore-ingredient1
Crabcore-ingredient1
Crustaceanscore-ingredient1
en:barscore-ingredient1
Products without glutencore-ingredient1
Products for specific dietscore-ingredient1
Preparaciones de bebidascore-ingredient1
Bebidas y preparaciones de bebidascore-ingredient1
Smoked sausagescore-ingredient1
fr:Dessert glacé aux fruitscore-ingredient1
Peanut butter cupscore-ingredient1
hu:rágógumicore-ingredient1
Sushi medleycore-ingredient1
Alaska pollockcore-ingredient1
Whitingcore-ingredient1
Pollockscore-ingredient1
Lean fishescore-ingredient1
fr:Gommescore-ingredient1
Fudgescore-ingredient1
Fruit biscuitscore-ingredient1
Candy chocolate barscore-ingredient1
Gum and mintscore-ingredient1
Pound Cakecore-ingredient1
Salad dressingscore-ingredient1
Mustardscore-ingredient1
fr:Pâtes au Yuzucore-ingredient1
Easter eggscore-ingredient1
Chocolate eggscore-ingredient1
Easter foodcore-ingredient1
Canned tunascore-ingredient1
Tunascore-ingredient1
Canned fishescore-ingredient1
Fatty fishescore-ingredient1
Cookies with chocolate and coconutcore-ingredient1
Biscuits/Cookiescore-ingredient1
Cookie with chocolate coveringcore-ingredient1
Sandwich cookiescore-ingredient1
Sugar-free flavoured syrupscore-ingredient1
Pickled cucumberscore-ingredient1
Vegetable-picklescore-ingredient1
Canned vegetablescore-ingredient1
Stuffingcore-ingredient1
Fruits enrobés de chocolatcore-ingredient1
Confiseries aux fruitscore-ingredient1
Open Products Factscore-ingredient1
Milk chocolate barcore-ingredient1
shampuicore-ingredient1
Comprimés à sucercore-ingredient1
Oral Healthcore-ingredient1
Cheesecakescore-ingredient1
Iced teascore-ingredient1
Teascore-ingredient1
Cacahuètes grilléescore-ingredient1
Cacahuètescore-ingredient1
Fruits à coque grilléscore-ingredient1
Légumineusescore-ingredient1
Légumineuses et dérivéscore-ingredient1
en:medikamentecore-ingredient1
Corned-beefcore-ingredient1
Beef dishescore-ingredient1
Meals with meatcore-ingredient1
supplamentscore-ingredient1
Bakery productscore-ingredient1
Lozengescore-ingredient1
Flakescore-ingredient1
Cauliflower crust pizzacore-ingredient1
Pizzascore-ingredient1
Pizzas pies and quichescore-ingredient1
Homeopathiccore-ingredient1
Milk chocolatescore-ingredient1
Cajetacore-ingredient1
en:peanut-butterscore-ingredient1
es:Crema de cacahuatecore-ingredient1
Canned fruits in juicecore-ingredient1
Kimchicore-ingredient1
Marble cakescore-ingredient1
Chocolate snack bar dairy filling with sponge cakecore-ingredient1
Gummy candiescore-ingredient1
Sour snakescore-ingredient1
Surimi on stickscore-ingredient1
en:gumcore-ingredient1
Energy Gumcore-ingredient1
Bean spreadscore-ingredient1
Salted spreadscore-ingredient1
Meat analoguescore-ingredient1
Gummy chipscore-ingredient1
Herbscore-ingredient1
Cereal bar with almondscore-ingredient1
Cereal bar with almonds or hazelnutscore-ingredient1
Nuts cereal barscore-ingredient1
Muesliscore-ingredient1
Breakfast cerealscore-ingredient1
Cabbagescore-ingredient1
Leaf vegetablescore-ingredient1
Shake proteinecore-ingredient1
Crema de cacahuatecore-ingredient1
Sponge cake biscuits with fruits coveringcore-ingredient1
Amandelmarsepeincore-ingredient1
Marsepeincore-ingredient1
en:cooked-turkey-breast-slicescore-ingredient1
es:Pechuga de pavo cocidocore-ingredient1
Macarons à la noix de cococore-ingredient1
Boudoirscore-ingredient1
Aliments et boissons d'Halloweencore-ingredient1
en:dessert-mixescore-ingredient1
Sugary cooking helperscore-ingredient1
Aide à la perte de poidscore-ingredient1
Pastillescore-ingredient1
Pastilles de Vichycore-ingredient1
Noix de cajoucore-ingredient1
Fruits à coque saléscore-ingredient1
Crêpes fourrées au chocolatcore-ingredient1
Crêpes fourrées sucréescore-ingredient1
Crêpes fourréescore-ingredient1
Crêpescore-ingredient1
Crêpes et galettescore-ingredient1
Soupescore-ingredient1
Nouilles instantanéescore-ingredient1
Nouillescore-ingredient1
Produits lyophilisés à reconstituercore-ingredient1
Pâtes alimentairescore-ingredient1
Céréales et dérivéscore-ingredient1
Gressinscore-ingredient1
Tartes au citroncore-ingredient1
en:Strawberry short cakecore-ingredient1
Tartes aux fraisescore-ingredient1
Alimentscore-ingredient1
Xcore-ingredient1
Naturescore-ingredient1
Palmierscore-ingredient1
Biscuits feuilletéscore-ingredient1
Biscuits sabléscore-ingredient1
Preparations-made-from-fish-meatcore-ingredient1
Noix de Saint-Jacquescore-ingredient1
Mollusquescore-ingredient1
de Saint-Jacquescore-ingredient1
Terrines de poissoncore-ingredient1
Sorbets au citroncore-ingredient1
en:chocolate-dessertscore-ingredient1
en:milk-chocolatescore-ingredient1
Madeleines fourréescore-ingredient1
Sorbets à la manguecore-ingredient1
Gâteaux aux noixcore-ingredient1
Pains de miecore-ingredient1
Cakes aux fruitscore-ingredient1
Pâtes à tartinercore-ingredient1
Produits à tartiner sucréscore-ingredient1
Produits à tartinercore-ingredient1
Brochettes de porccore-ingredient1
Pruneauxcore-ingredient1
Chocolate-cake-with-melting-centrecore-ingredient1
édulcoréescore-ingredient1
Gâteau moelleux fourré aux fruitscore-ingredient1
en:preparations-made-from-fish-meatcore-ingredient1
Bâtonnets de surimicore-ingredient1
Délice gourmandcore-ingredient1
Chocolats noirs au cafécore-ingredient1
Cookiescore-ingredient1
Coulis de myrtillecore-ingredient1
en:chocolate-cakescore-ingredient1
Truffes en chocolatcore-ingredient1
Menthe poivréecore-ingredient1
Menthecore-ingredient1
en:aromatic-herbscore-ingredient1
Plantes aromatiquescore-ingredient1
Plantes condimentairescore-ingredient1
Barres énergétiquescore-ingredient1
Compléments pour le Bodybuildingcore-ingredient1
en:Beveragescore-ingredient1
Stolencore-ingredient1
sv:Tuggummicore-ingredient1
without sugarcore-ingredient1
Konfektcore-ingredient1
Söta snackscore-ingredient1
Chewingcore-ingredient1
en:ДЪВКИcore-ingredient1
Дъвки без захарcore-ingredient1
Дъвкиcore-ingredient1
Pains d'épicescore-ingredient1
tooth pastecore-ingredient1
sirop medicamentcore-ingredient1
Crème de mainscore-ingredient1
de:Mundspülungcore-ingredient1
ro:Guma de mestecatcore-ingredient1
de:Zahnpastacore-ingredient1
Proteinriegelcore-ingredient1
Nahrungsergänzungen für Bodybuildercore-ingredient1
Nahrungsergänzungsmittelcore-ingredient1
Kekse und Kuchencore-ingredient1
Hustenpastillencore-ingredient1
Medizinproduktecore-ingredient1
ru:Hand creamcore-ingredient1
Creamscore-ingredient1
Puffed rice cakescore-ingredient1
Puffed cereal cakescore-ingredient1
en:Mochicore-ingredient1
Milk custard cream-filled Vanilla Cake barcore-ingredient1
Mamoncore-ingredient1
Sponge cakescore-ingredient1
Health-carecore-ingredient1
Produit importécore-ingredient1
ja:辛子明太子core-ingredient1
Smoked cod roecore-ingredient1
Semi-preserved foodscore-ingredient1
Fish eggscore-ingredient1
Fish and meat and eggscore-ingredient1
en:Non food productscore-ingredient1
en:dietary-supplementscore-ingredient1
en:meat-analoguescore-ingredient1
Prodotti non alimentaricore-ingredient1
Chocolate soft cakecore-ingredient1
de:Pastillecore-ingredient1
Blue raspberrycore-ingredient1
Gummy cola bottlescore-ingredient1
Oatmeal cookiescore-ingredient1
en:chocolatescore-ingredient1
bs:Soft biscuitcore-ingredient1
bs:Cake biscuitcore-ingredient1
Biscuit sec au laitcore-ingredient1
en:Cake moelleuxcore-ingredient1
Tartelettes à la framboisecore-ingredient1
Black chocolat kookiecore-ingredient1
Sugar-free mintscore-ingredient1
Candy mintscore-ingredient1
de chocolatecore-ingredient1
Boloscore-ingredient1
Biscoitos e Boloscore-ingredient1
Jam preservecore-ingredient1
Blackcurrant jamscore-ingredient1
Berry jamscore-ingredient1
Mixed fruit jamscore-ingredient1
Barres de céréales au chocolatcore-ingredient1
Barres de céréalescore-ingredient1
uk:батончик-шоколаднийcore-ingredient1
Gingerbreadscore-ingredient1
en:apricot-jamscore-ingredient1
flavoured jelliescore-ingredient1
Croissants fourrés au chocolatcore-ingredient1
Croissants fourréscore-ingredient1
en:Sweet pastries and piescore-ingredient1
Biscuits au chocolatcore-ingredient1
Génoisecore-ingredient1
Chocolat blanc en tablettecore-ingredient1
Chocolats blancscore-ingredient1
en:Assortments of biscuitscore-ingredient1
كعكcore-ingredient1
بسكويتcore-ingredient1
Beignets fourrés au chocolatcore-ingredient1
fr:Sponge Cake au cacaocore-ingredient1
Muffin au abricotcore-ingredient1
Chocolate biscuitscore-ingredient1
Chocolate chip muffinscore-ingredient1
Blondiescore-ingredient1
en:biscuit-with-fruit-coveringcore-ingredient1
Tartelettes à l'abricotcore-ingredient1
Tartletscore-ingredient1
Piescore-ingredient1
Sweet piescore-ingredient1
Moisturecore-ingredient1
fr:Dentifricescore-ingredient1
Iskremcore-ingredient1
en:Ice creams and sorbetscore-ingredient1
en:Frozen dessertscore-ingredient1
en:Frozen foodscore-ingredient1
en:Browniescore-ingredient1
en:Chocolate cakescore-ingredient1
en:Chocolate biscuitscore-ingredient1
Kjekscore-ingredient1
en:Liquorice candiescore-ingredient1
Instant noodlescore-ingredient1
Noodlescore-ingredient1
en:toothpastecore-ingredient1
Soincore-ingredient1
Pastelilloscore-ingredient1
Cajetascore-ingredient1
Pastelitoscore-ingredient1
Bimbocore-ingredient1
PASTELITOcore-ingredient1
es:PASTELITOcore-ingredient1
Panescore-ingredient1
en:artificially-sweetened-beveragescore-ingredient1
es:Bebidas de frutascore-ingredient1
Unsweetened beveragescore-ingredient1
Jugoscore-ingredient1
Boissons édulcoréescore-ingredient1
Boissons aux fruitscore-ingredient1
Boissons à base de végétauxcore-ingredient1
Galletas sin azúcarcore-ingredient1
Mielescore-ingredient1
Productos agrícolascore-ingredient1
Productos apícolascore-ingredient1
en:chiclescore-ingredient1
Productos artesanalescore-ingredient1
Barra cerealcore-ingredient1
Produtos não alimentarescore-ingredient1
Édulcorant à l'aspartame en pastillescore-ingredient1
Aspartamescore-ingredient1
Édulcorants artificielscore-ingredient1
Succédanés du sucrecore-ingredient1
Additifs alimentairescore-ingredient1
Marrons glacéscore-ingredient1
Confiseries de fruits à coquescore-ingredient1
Sauces sucréescore-ingredient1
Sauce au chocolatcore-ingredient1
Produit au mentolcore-ingredient1
Bonbons au mentolcore-ingredient1
Bonbons aux Plantescore-ingredient1
Gâteau moelleux au chocolatcore-ingredient1
Pastilhas elásticascore-ingredient1
Gomascore-ingredient1
Rebuçados e gomascore-ingredient1
en:Caramelos de gomacore-ingredient1
en:Acid gummy candiescore-ingredient1
Heladocore-ingredient1
Helados y sorbetescore-ingredient1
Postres heladoscore-ingredient1
Congeladoscore-ingredient1
Barrita de cereales con almendras o avellanascore-ingredient1
en:Nuts cereal barscore-ingredient1
en:Milk chocolates with sweetenerscore-ingredient1
en:Milk chocolate barcore-ingredient1
Christmas sweetscore-ingredient1
Christmas foods and drinkscore-ingredient1
Preparaciones de pescadocore-ingredient1
Pescadoscore-ingredient1
en:pound-cakecore-ingredient1
es:Budincore-ingredient1
en:filled-biscuitscore-ingredient1
Galletitascore-ingredient1
Sconscore-ingredient1
en:strawberry-jamscore-ingredient1
Productoscore-ingredient1
Mermeladas y confituras dietécore-ingredient1
Milk jamscore-ingredient1
en:protein-barscore-ingredient1
Barritas de proteínascore-ingredient1
Barritas de cereales con chocolatecore-ingredient1
Barritas energéticascore-ingredient1
es:barra de cerealcore-ingredient1
en:Milk chocore-ingredient1
en:Filled milk chocolatescore-ingredient1
Chocolate rellenocore-ingredient1
Mermeladascore-ingredient1
Mermeladacore-ingredient1
en:sweetened-beveragescore-ingredient1
Beverages and beverages preparationscore-ingredient1
pl:Pasta do zębówcore-ingredient1
en:Caramelscore-ingredient1
Pães sem glútencore-ingredient1
en:Flatbreadscore-ingredient1
Produtos sem glútemcore-ingredient1
Pãescore-ingredient1
Cereais e Batatascore-ingredient1
en:Chocolate covered coconut ballscore-ingredient1
Doces de natalcore-ingredient1
Alimentos e bebidas de natalcore-ingredient1
Bombons de chocolatecore-ingredient1
en:Festive foodscore-ingredient1
Cacau e derivadoscore-ingredient1
Confiserie sans sucrecore-ingredient1
Bonbons au réglissecore-ingredient1
Stévia et dérivéscore-ingredient1
en:Pastilles aromatiséescore-ingredient1
en:Mint candycore-ingredient1
en:Bonbon-menthecore-ingredient1
Gomme da masticarecore-ingredient1
Filled sponge cake slicescore-ingredient1
ro:Pasta dințicore-ingredient1
Tortacore-ingredient1
Biscotti e tortecore-ingredient1
Panettonecore-ingredient1
Briochescore-ingredient1
Chewing gum sans sucrescore-ingredient1
en:Chewing-gum sans sucrescore-ingredient1
fr:Chewing-gum à la chlorophyllecore-ingredient1
Bonbons-🍬core-ingredient1
Sugar-free tabletscore-ingredient1
Konfekturecore-ingredient1
Søde snackscore-ingredient1
Chewing gum in paper boxcore-ingredient1
fr:Bonbons dragéifiéscore-ingredient1
Vitamine Ccore-ingredient1
Vitamine B6core-ingredient1
Vitamine B12core-ingredient1
Tapascore-ingredient1
Brochettes decore-ingredient1
Plats préparés à réchauffer au micro-ondescore-ingredient1
Plats préparés fraiscore-ingredient1
Tourons crémeux aux amandescore-ingredient1
Tourons au jaune d'œuf grillécore-ingredient1
Nougatscore-ingredient1
en:Yogurt cakecore-ingredient1
Postres lácteoscore-ingredient1
Pasteles de chocolatecore-ingredient1
Charcuteries cuitescore-ingredient1
Charcuteriescore-ingredient1
Beignets saléscore-ingredient1
Tourons croquants aux amandescore-ingredient1
en:Biscuit with vegetal fatcore-ingredient1
Galletas secascore-ingredient1
en:Botanas Snacks dulces Galletas y pasteles Pasteles Magdalenascore-ingredient1
Panes de higoscore-ingredient1
Alimentos de origen vegetal deshidratadoscore-ingredient1
Productos deshidratadoscore-ingredient1
Dátilescore-ingredient1
Cooked turkey breast slicescore-ingredient1
Poultry hamscore-ingredient1
en:pasteleriacore-ingredient1
en:madeleinescore-ingredient1
Kouglofcore-ingredient1
Reposteríacore-ingredient1
Snoepcore-ingredient1
Pechuga de pavocore-ingredient1
Pechugas de pollocore-ingredient1
Pollocore-ingredient1
Pollo y sus productoscore-ingredient1
Jamón cocido ahumadocore-ingredient1
en:Poultry hamscore-ingredient1
Jamón cocido de pollocore-ingredient1
Sobao Pasiegocore-ingredient1
en:Spanish bakery productscore-ingredient1
Productos de panaderíacore-ingredient1
en:Chocolate chip muffinscore-ingredient1
Dragées à la menthecore-ingredient1
Dragéescore-ingredient1
fr:Bonbons à la menthecore-ingredient1
Cocoscore-ingredient1
Frutas tropicalescore-ingredient1
Pastillascore-ingredient1
Nougatcore-ingredient1
Turrones de chocolatecore-ingredient1
Mermeladas y confituras de frcore-ingredient1
Sponge cake filled and covered with chocolatecore-ingredient1
Sponge-cakecore-ingredient1
en:Десертcore-ingredient1
Суфлеcore-ingredient1
Kekcore-ingredient1
Bisküviler ve keklercore-ingredient1
Atıştırmalıklarcore-ingredient1
ro:prăjitură cu lămâiecore-ingredient1
biscuits cookies au chocolatcore-ingredient1
Glace en potcore-ingredient1
Crèmes glacées en potcore-ingredient1
Glacescore-ingredient1
fr:fouets-catalanscore-ingredient1
Fuet met zwarte pepercore-ingredient1
Fish fingerscore-ingredient1
Breaded fishcore-ingredient1
Breaded productscore-ingredient1
au poissoncore-ingredient1
en:Surimi chipcore-ingredient1
en:Surimicore-ingredient1
en:Fish preparationscore-ingredient1
en:Fishescore-ingredient1
อาหารทะเลcore-ingredient1
whole meal breadcore-ingredient1
Whole-meal-breadcore-ingredient1
Bran sliced breadscore-ingredient1
Still fruit soft drink with sugar and with less than 10% of fruit juicecore-ingredient1
en:iced-teascore-ingredient1
Mouthwashcore-ingredient1
Codliver fatscore-ingredient1
Fish oilscore-ingredient1
Animal fatscore-ingredient1
Chewing-gum Sugarfreecore-ingredient1
Bakerycore-ingredient1
Coconutscore-ingredient1
Tropical fruitscore-ingredient1
Milkscore-ingredient1
Sugarfree chewing gumcore-ingredient1
Ibuprofen soft gel capsulescore-ingredient1
Barbecue saucescore-ingredient1
Sugar free mintcore-ingredient1

Roles (9)

RoleDescription
sweetening agentSubstance that sweeten food, beverages, medications, etc.
laxativeAn agent that produces a soft formed stool, and relaxes and loosens the bowels, typically used over a protracted period, to relieve constipation. Compare with cathartic, which is a substance that accelerates defecation. A substances can be both a laxative and a cathartic.
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
catharticAny substance that accelerates defecation. Compare with laxatives, which are substances that ease defecation (usually by softening faeces). A substance can be both a laxative and a cathartic.
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
food humectantA humectant that is used as a food additive to prevent foodstuffs from drying out.
Saccharomyces cerevisiae metaboliteAny fungal metabolite produced during a metabolic reaction in Baker's yeast (Saccharomyces cerevisiae).
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
hexitol
glucitol
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (30)

PathwayProteinsCompounds
Metabolism14961108
Carbohydrate metabolism173120
Fructose metabolism721
Fructose biosynthesis29
Galactose Metabolism1234
Fructose and Mannose Degradation1830
Galactosemia1234
Fructosuria1830
Fructose Intolerance, Hereditary1830
sorbitol biosynthesis II010
D-sorbitol biosynthesis I115
D-sorbitol degradation I112
Fructose and Mannose metabolism ( Fructose and Mannose metabolism )2527
NAD+ + D-Sorbitol = NADH + D-Fructose ( Fructose and Mannose metabolism )14
NADP+ + D-Sorbitol = NADPH + D-Glucose ( Fructose and Mannose metabolism )14
sorbitol degradation I19
2-keto-L-gulonate biosynthesis417
superpathway of microbial D-galacturonate and D-glucuronate degradation3592
D-sorbitol degradation I512
D-galactose degradation IV59
superpathway of u03B2-D-glucuronosides degradation1136
L-ascorbate biosynthesis III110
D-fructuronate degradation829
superpathway of hexuronide and hexuronate degradation838
sorbitol biosynthesis II211
sorbitol degradation49
galactose degradation IV013
sorbitol biosynthesis I08
sorbose utilization03
Hexoses metabolism in proximal tubules016
Biochemical pathways: part I0466
Polyol pathway08

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency70.79460.003245.467312,589.2998AID2517
lamin isoform A-delta10Homo sapiens (human)Potency8.42440.891312.067628.1838AID1487
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency23.77810.003245.467312,589.2998AID2517
RAR-related orphan receptor gammaMus musculus (house mouse)Potency5.21640.006038.004119,952.5996AID1159521
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency10.50380.023723.228263.5986AID743222
chromobox protein homolog 1Homo sapiens (human)Potency2.81840.006026.168889.1251AID540317
flap endonuclease 1Homo sapiens (human)Potency89.12510.133725.412989.1251AID588795
gemininHomo sapiens (human)Potency0.10320.004611.374133.4983AID624296
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (56)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID687624Activity of Bacillus stearothermophilus alpha-glucosidase assessed as production of p-nitrophenol using p-nitrophenyl-alpha-D-glucopyranoside as substrate at 50 mM after 3 mins by spectrophotometer2011Bioorganic & medicinal chemistry, May-15, Volume: 19, Issue:10
Cellular zwitterionic metabolite analogs simultaneously enhance reaction rate, thermostability, salt tolerance, and substrate specificity of α-glucosidase.
AID687625Activity of Saccharomyces cerevisiae alpha-glucosidase assessed as production of p-nitrophenol using p-nitrophenyl-alpha-D-glucopyranoside as substrate at 50 mM after 3 mins by spectrophotometer2011Bioorganic & medicinal chemistry, May-15, Volume: 19, Issue:10
Cellular zwitterionic metabolite analogs simultaneously enhance reaction rate, thermostability, salt tolerance, and substrate specificity of α-glucosidase.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID389349Activation of 5-AMP-induced AMPKalpha in rat L6 cells assessed as Tyr172 phosphorylation at 0.25 M relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Novel D-xylose derivatives stimulate muscle glucose uptake by activating AMP-activated protein kinase alpha.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID687626Activity of commercial yeast alpha-glucosidase assessed as production of p-nitrophenol using p-nitrophenyl-alpha-D-glucopyranoside as substrate at 50 mM after 3 mins by spectrophotometer2011Bioorganic & medicinal chemistry, May-15, Volume: 19, Issue:10
Cellular zwitterionic metabolite analogs simultaneously enhance reaction rate, thermostability, salt tolerance, and substrate specificity of α-glucosidase.
AID30433Compound was tested for inhibition of Human acrosin by polyols1981Journal of medicinal chemistry, Nov, Volume: 24, Issue:11
Inhibition of human acrosin by monosaccharides and related compounds: structure-activity relationships.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6,154)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903022 (49.11)18.7374
1990's1027 (16.69)18.2507
2000's1054 (17.13)29.6817
2010's798 (12.97)24.3611
2020's253 (4.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 98.98

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index98.98 (24.57)
Research Supply Index3.78 (2.92)
Research Growth Index5.31 (4.65)
Search Engine Demand Index182.72 (26.88)
Search Engine Supply Index2.10 (0.95)

This Compound (98.98)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials359 (5.50%)5.53%
Reviews1 (2.33%)6.00%
Reviews306 (4.69%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies157 (2.40%)4.05%
Observational0 (0.00%)0.25%
Observational4 (0.06%)0.25%
Other42 (97.67%)84.16%
Other5,704 (87.35%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (27)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
An Open-label Study to Evaluate the Effect of Activated Charcoal With Sorbitol on the Pharmacokinetics of Mavacamten in Healthy Participants [NCT05320094]Phase 145 participants (Actual)Interventional2022-04-15Completed
Gait Analysis Following Single-shot Hyaluronic Acid Supplementation: a Pilot Randomised Double-blinded Clinical Trial [NCT03636971]Phase 2/Phase 322 participants (Actual)Interventional2013-05-01Completed
A Randomized Controlled Study of the Effect of Treatment of Low Anterior Resection Syndrome (LARS) After Rectal Cancer Surgery [NCT03215017]45 participants (Actual)Interventional2017-05-15Completed
Xylitol and Sorbitol Effects on the Microbiome of Saliva and Plaque [NCT03668015]29 participants (Actual)Interventional2015-03-05Completed
Interaction Between Cannabidiol, Meal Ingestion, and Liver Function [NCT04971837]26 participants (Actual)Interventional2021-05-20Completed
A SINGLE-BLIND, RANDOMIZED, MULTIPLE-PERIOD STUDY IN HEALTHY ADULT VOLUNTEERS TO INVESTIGATE THE PALATABILITY OF PROTOTYPE AGE APPROPRIATE ORAL FORMULATIONS OF BOSUTINIB FOR PEDIATRIC USE [NCT03747679]Phase 18 participants (Actual)Interventional2018-11-22Completed
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Assess the Efficacy and Safety of PXT3003 in Charcot-Marie-Tooth Type 1A (CMT1A) Treated 15 Months [NCT05092841]Phase 3176 participants (Anticipated)Interventional2021-09-28Recruiting
Bifidobacterium Lactis BB12 and Xylitol Delivered With a Novel Slow-release Pacifier [NCT00638677]Phase 4106 participants (Actual)Interventional2004-06-30Completed
Effect of Erythritol and Xylitol on Dental Caries Prevention in Children [NCT01062633]Phase 2/Phase 3450 participants (Anticipated)Interventional2008-01-31Recruiting
Preoperative Bowel Preparation Versus no Preparation Before Spinal Surgery: a Randomised Clinical Trial [NCT01879605]Phase 445 participants (Actual)Interventional2007-12-31Completed
Incidence and Severity of Parenteral Nutrition Associated Cholestasis in Neonates Subjected to Major Surgery, Using Two Mixed Intravenous Lipid Emulsions [NCT02633384]Phase 452 participants (Actual)Interventional2011-08-31Terminated(stopped due to One of the intravenous lipid emulsions was retired from the market)
Safe Excipient Exposure in Neonates and Small ChildreN - a Retrospective, Descriptive Study Off the Amount of Ethanol, Propylene Glycol, Benzyl Alcohol, Parabens, Acesulfam k, Aspartame, Glycerol, Sorbitol and Polysorbate-80 Exposed to Pediatric Patients [NCT02545712]630 participants (Actual)Observational2016-01-31Active, not recruiting
A Randomised, Controlled, Double-Blind Study to Examine Nicotine Pharmacokinetics and Smoking Behaviour in Healthy Smokers When Smoking Cigarettes Containing Different Commonly Used Ingredients [NCT03272295]40 participants (Actual)Interventional2017-09-12Completed
A Multi-center, Randomized, Single-blind Clinical Study of the Comparative Safety and Efficacy of Docusate Sodium and Sorbitol Rectal Solution and Glycerine Enemas in Patients With Constipation [NCT01474499]Phase 3300 participants (Actual)Interventional2011-09-30Completed
Enhancing Brain Development by Early Iron Supplementation of African Infants: An Enabling Pilot Study [NCT04751994]Phase 3100 participants (Actual)Interventional2021-08-03Completed
A Phase 2, Randomised, Placebo Controlled Study to Evaluate the Efficacy, Tolerability and Safety of Metabolic Cofactor Supplementation in Obese Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD) [NCT04330326]Phase 245 participants (Anticipated)Interventional2019-07-20Recruiting
ZG-801 Phase III Trial - Randomized, Double-blind, Placebo-controlled Trial of ZG-801 in Patients With Hyperkalemia - [NCT04955678]Phase 385 participants (Actual)Interventional2021-08-03Completed
Safety and Effectiveness of Hyaluronic Acid and Sorbitol With Overuse Knee Pain in Sportsmen [NCT05450458]Phase 2/Phase 360 participants (Anticipated)Interventional2022-07-01Recruiting
A Multi Centre, Randomised, Controlled, Open-Label Phase 2/3 Study to Evaluate The Efficacy, Tolerability and Safety of Metabolic Cofactor Supplementation and Hydroxychloroquine Combination in Covid-19 Patients [NCT04573153]Phase 2/Phase 3400 participants (Anticipated)Interventional2020-09-21Recruiting
A Multi-center, Randomized, Double-blind, Placebo Controlled Phase III Study to Assess the Efficacy, Safety, and Tolerability of PXT3003 in Charcot-Marie-Tooth Type 1A (CMT1A) [NCT04762758]Phase 3350 participants (Anticipated)Interventional2021-03-30Active, not recruiting
Xylitol for the Prevention of Acute Otitis Media Episodes in Children 2-4: A Pragmatic RCT [NCT03055091]472 participants (Anticipated)Interventional2017-03-31Recruiting
A Comparative, Randomized, Evaluator-Blind, Parallel-Group Clinical Study of the Effect of Two Experimental Lozenges on Oral Malodor After Single Use [NCT05950529]156 participants (Actual)Interventional2020-02-06Completed
An Open-label Single-Center, 4-Period William's Cross-Over Design Drug Interaction Trial to Determine the Effects of Sorbitol-Containing Solutions on Lamivudine Exposure Following Administration of Lamivudine Oral Solution in Healthy Adult Subjects [NCT02634073]Phase 416 participants (Actual)Interventional2016-01-01Completed
A Randomized, Double-Blind, Single-Center, 5 Way Cross-Over Study to Assess the Effect of Adding Oral Phenylephrine and Oral Sorbitol to Low Dose (1.5 mg) Plain Oral Morphine in Human Volunteers: Analgesia and Side Effect Assessment. [NCT00374881]Phase 1/Phase 29 participants (Actual)Interventional2006-09-30Completed
The Effect of the Frequent Xylitol Chewing Gum Use on the Oral Microbiota in Children With High MS Counts [NCT01528969]Phase 1/Phase 2122 participants (Actual)Interventional2012-03-31Completed
The Effect of a Mixture of 2.7% Sorbitol-0.54% Mannitol Solution on Blood Coagulation: In-vitro, Observational Healthy-volunteer Study Using Rotational Thromboelastometry (ROTEM®) [NCT03105180]12 participants (Actual)Observational2017-03-10Completed
A Phase 2, Randomized, Placebo Controlled Study to Evaluate the Efficacy, Tolerability and Safety of Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) And Parkinson's Disease (PD) Patients [NCT04044131]Phase 2120 participants (Actual)Interventional2019-12-02Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01528969 (1) [back to overview]MS Counts of Stimulated Saliva
NCT02634073 (20) [back to overview]Lamivudine Elimination Half-life in Plasma (t1/2)
NCT02634073 (20) [back to overview]Plasma Lamivudine Apparent Oral Clearance (CL/F)
NCT02634073 (20) [back to overview]Change From Baseline in Albumin
NCT02634073 (20) [back to overview]Change From Baseline in Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) and Alkaline Phosphates
NCT02634073 (20) [back to overview]Change From Baseline in Blood Urea Nitrogen (BUN), Sodium, Potassium, Glucose, Calcium
NCT02634073 (20) [back to overview]Change From Baseline in Body Temperature
NCT02634073 (20) [back to overview]Change From Baseline in Creatinine, Total Bilirubin and Direct Bilirubin
NCT02634073 (20) [back to overview]Change From Baseline in Erythrocytes
NCT02634073 (20) [back to overview]Change From Baseline in Hematocrit
NCT02634073 (20) [back to overview]Change From Baseline in Hemoglobin
NCT02634073 (20) [back to overview]Change From Baseline in Mean Corpuscular Hemoglobin (MCH)
NCT02634073 (20) [back to overview]Change From Baseline in Mean Corpuscular Volume (MCV)
NCT02634073 (20) [back to overview]Change From Baseline in Platelets, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils
NCT02634073 (20) [back to overview]Change From Baseline in Pulse Rate
NCT02634073 (20) [back to overview]Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
NCT02634073 (20) [back to overview]Number of Participants With Any Adverse Events (AEs) and Any Serious Adverse Events (SAE)
NCT02634073 (20) [back to overview]Number of Participants With Treatment Emergent Laboratory Abnormality Grade
NCT02634073 (20) [back to overview]Plasma Lamivudine Area Under the Plasma Concentration Time Curve (AUC) From Time Zero to the Last Quantifiable Time Point (AUC[0-t]), AUC From Time Zero Extrapolated to Infinity (AUC[0-inf]) and AUC From Time Zero to 24 Hours (AUC[0-24])
NCT02634073 (20) [back to overview]Plasma Lamivudine Maximum Observed Concentration (Cmax), Concentration at 24 Hour (h) Post-dose (C24) and Last Measurable Concentration (Ct)
NCT02634073 (20) [back to overview]Time to Observed Maximum Lamivudine Plasma Concentration (Tmax), Time of Last Measurable Plasma Concentration (Tlast) and Absorption Lag Time in Plasma (Tlag)

MS Counts of Stimulated Saliva

The MS counts were measured at the beginning and in the end of the 5 weeks intervention (NCT01528969)
Timeframe: 5 weeks

,
InterventionMS counts log CFU/ml (Mean)
Baseline5-week follow-up
Sorbitol4.403.78
Xylitol4.864.29

[back to top]

Lamivudine Elimination Half-life in Plasma (t1/2)

Serial blood sample were collected at Pre-dose; 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 16, 24, 36 and 48 hours post-dose in each treatment period. ANOVA, considering treatment and period as fixed effects and participant as random effect, was performed using Mixed Linear Models procedure to compare the plasma lamivudine t1/2. (NCT02634073)
Timeframe: Day 1 to Day 3 in each treatment period

InterventionHour (Hr) (Geometric Mean)
A: Lamivudine 300 mg13.9
B: Lamivudine 300 mg + Sorbitol 3.2 g19.0
C: Lamivudine 300 mg + Sorbitol 10.2 g21.2
D: Lamivudine 300 mg + Sorbitol 13.4 g17.3

[back to top]

Plasma Lamivudine Apparent Oral Clearance (CL/F)

Serial blood sample were collected at Pre-dose; 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 16, 24, 36 and 48 hours post-dose in each treatment period. ANOVA, considering treatment and period as fixed effects and participant as random effect, was performed using Mixed Linear Models procedure to compare the plasma lamivudine CL/F (NCT02634073)
Timeframe: Day 1 to Day 3 in each treatment period

InterventionLiter (L)/hr (Geometric Mean)
A: Lamivudine 300 mg22.738
B: Lamivudine 300 mg + Sorbitol 3.2 g26.621
C: Lamivudine 300 mg + Sorbitol 10.2 g33.608
D: Lamivudine 300 mg + Sorbitol 13.4 g34.875

[back to top]

Change From Baseline in Albumin

Blood samples were collected at Day -1, Day 3 of every treatment period and at follow-up. Change from Baseline for albumin was calculated as the post-dose Visit Value minus the value at Baseline, at Day 3 and Follow-up. Baseline value used in the analysis was the latest pre-dose values on Day 1 of each treatment/Period. Day -1 presented the Baseline absolute values; Day 3 and Follow-Up presented the changes from Baseline. (NCT02634073)
Timeframe: Baseline and up to 5 weeks

,,,
InterventionG//L (Mean)
Day 3Follow up
A: Lamivudine 300 mg1.80.6
B: Lamivudine 300 mg + Sorbitol 3.2 g2.30.6
C: Lamivudine 300 mg + Sorbitol 10.2 g2.10.6
D: Lamivudine 300 mg + Sorbitol 13.4 g2.10.6

[back to top]

Change From Baseline in Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) and Alkaline Phosphates

Blood samples were collected at Day -1, Day 3 of every treatment period and at follow-up. Change from Baseline for AST, ALT and alkaline phosphatase were calculated as the post-dose visit value minus the value at Baseline, at Day 3 and Follow-up. Baseline value used in the analysis was the latest pre-dose values on Day 1 of each treatment/period. Day -1 presented the Baseline absolute values; Day 3 and Follow-Up presented the changes from Baseline. (NCT02634073)
Timeframe: Baseline and up to 5 weeks

,,,
InterventionUnit (U)/L (Mean)
AST, Day 3AST, Follow upALT, Day 3ALT, Follow upAlkaline phosphatatse, Day 3Alkaline phosphatase, Follow up
A: Lamivudine 300 mg-3.11.1-2.20.4-0.41.2
B: Lamivudine 300 mg + Sorbitol 3.2 g-3.51.1-2.70.41.11.2
C: Lamivudine 300 mg + Sorbitol 10.2 g-2.31.1-2.20.41.51.2
D: Lamivudine 300 mg + Sorbitol 13.4 g-19.11.1-2.50.4-0.21.2

[back to top]

Change From Baseline in Blood Urea Nitrogen (BUN), Sodium, Potassium, Glucose, Calcium

Blood samples were collected at Day -1, Day 3 of every treatment period and at follow-up. Change from Baseline for BUN, sodium, potassium, glucose, calcium were calculated as the post-dose visit value minus the value at Baseline, at Day 3 and Follow-up. Baseline value used in the analysis was the latest pre-dose values on Day 1 of each treatment/period. Day -1 presented the Baseline absolute values; Day 3 and Follow-Up presented the changes from Baseline. (NCT02634073)
Timeframe: Baseline and up to 5 weeks

,,,
Interventionmillimole (mmol)/L (Mean)
BUN, Day 3BUN, Follow upSodium, Day 3Sodium, Follow upPotassium, Day 3Potassium, Follow upGlucose, Day 3Glucose, Follow upCalcium Day 3Calcium, Follow up
A: Lamivudine 300 mg-0.0892-0.4909-2.4-0.10.060.02-0.058970.339940.09060.0328
B: Lamivudine 300 mg + Sorbitol 3.2 g-0.5578-0.4909-1.2-0.10.090.020.055500.339940.11410.0328
C: Lamivudine 300 mg + Sorbitol 10.2 g0.0223-0.4909-2.6-0.10.190.020.013880.339940.11410.0328
D: Lamivudine 300 mg + Sorbitol 13.4 g0.0446-0.4909-2.0-0.10.060.02-0.031220.339940.08750.0328

[back to top]

Change From Baseline in Body Temperature

Change from Baseline for body temperature was calculated as the post-dose visit value minus the value at Baseline, at Day 3 and Follow-up. Baseline value used in the analysis was the latest pre-dose values on Day 1 of each treatment/period. (NCT02634073)
Timeframe: Baseline and up to 5 weeks

,,,
InterventionDegree centigrade (Mean)
Day 3Follow up
A: Lamivudine 300 mg0.03-0.01
B: Lamivudine 300 mg + Sorbitol 3.2 g0.07-0.01
C: Lamivudine 300 mg + Sorbitol 10.2 g0.08-0.01
D: Lamivudine 300 mg + Sorbitol 13.4 g-0.03-0.01

[back to top]

Change From Baseline in Creatinine, Total Bilirubin and Direct Bilirubin

Blood samples were collected at Day -1, Day 3 of every treatment period and at follow-up. Change from Baseline for creatinine and direct bilirubin were calculated as the post-dose visit value minus the value at Baseline, at Day 3 and Follow-up. Baseline value used in the analysis was the latest pre-dose values on Day 1 of each treatment/period. Change from Baseline in total bilirubine was not assessed. Day -1 presented the Baseline absolute values; Day 3 and Follow-Up presented the changes from Baseline. (NCT02634073)
Timeframe: Baseline and up to 5 weeks

,,,
Interventionmicromole (umol)/L (Mean)
Creatinine, Day 3Creatinine, Follow upDirect bilirubin, Day 3Direct bilirubin, Follow up
A: Lamivudine 300 mg3.867590.000000.6410.107
B: Lamivudine 300 mg + Sorbitol 3.2 g2.210050.000000.1070.107
C: Lamivudine 300 mg + Sorbitol 10.2 g4.420100.000000.1070.107
D: Lamivudine 300 mg + Sorbitol 13.4 g0.552510.000000.3210.107

[back to top]

Change From Baseline in Erythrocytes

Blood samples were collected at Day -1, Day 3 of every treatment period and at follow-up. Change from Baseline for erythrocytes was calculated as the post-dose visit value minus the value at Baseline, at Day 3 and Follow-up. Baseline value used in the analysis was the latest pre-dose values on Day 1 of each treatment/Period. Day -1 presented the Baseline absolute values; Day 3 and Follow-Up presented the changes from Baseline. (NCT02634073)
Timeframe: Baseline and up to 5 weeks

,,,
Intervention10^12 cells/L (Mean)
Day 3Follow up
A: Lamivudine 300 mg0.3510.142
B: Lamivudine 300 mg + Sorbitol 3.2 g0.3890.142
C: Lamivudine 300 mg + Sorbitol 10.2 g0.3390.142
D: Lamivudine 300 mg + Sorbitol 13.4 g0.3800.142

[back to top]

Change From Baseline in Hematocrit

Blood samples were collected at Day -1, Day 3 of every treatment period and at follow-up. Change from Baseline for hematocrit was calculated as the post-dose visit value minus the value at Baseline, at Day 3 and Follow-up. Baseline value used in the analysis was the latest pre-dose values on Day 1 of each treatment/period. Day -1 presented the Baseline absolute values; Day 3 and Follow-Up presented the changes from Baseline. (NCT02634073)
Timeframe: Baseline and up to 5 weeks

,,,
InterventionFraction of 1 (Mean)
Day 3Follow up
A: Lamivudine 300 mg0.03380.0091
B: Lamivudine 300 mg + Sorbitol 3.2 g0.03780.0091
C: Lamivudine 300 mg + Sorbitol 10.2 g0.03080.0091
D: Lamivudine 300 mg + Sorbitol 13.4 g0.03530.0091

[back to top]

Change From Baseline in Hemoglobin

Blood samples were collected at Day -1, Day 3 of every treatment period and at follow-up. Change from Baseline for hemoglobin was calculated as the post-dose visit value minus the value at Baseline, at Day 3 and Follow-up. Baseline value used in the analysis was the latest pre-dose values on Day 1 of each treatment/period. Day -1 presented the Baseline absolute values; Day 3 and Follow-Up presented the changes from Baseline. (NCT02634073)
Timeframe: Baseline and up to 5 weeks

,,,
InterventionG/L (Mean)
Day 3Follow up
A: Lamivudine 300 mg10.13.4
B: Lamivudine 300 mg + Sorbitol 3.2 g10.93.4
C: Lamivudine 300 mg + Sorbitol 10.2 g9.83.4
D: Lamivudine 300 mg + Sorbitol 13.4 g9.93.4

[back to top]

Change From Baseline in Mean Corpuscular Hemoglobin (MCH)

Blood samples were collected at Day -1, Day 3 of every treatment period and at follow-up. Change from Baseline for MCH was calculated as the post-dose visit value minus the value at Baseline, at Day 3 and Follow-up. Baseline value used in the analysis was the latest pre-dose values on Day 1 of each treatment/period. Day -1 presented the Baseline absolute values; Day 3 and Follow-Up presented the changes from Baseline. (NCT02634073)
Timeframe: Baseline and up to 5 weeks

,,,
InterventionPicogram (Mean)
Day 3Follow up
A: Lamivudine 300 mg0.02-0.14
B: Lamivudine 300 mg + Sorbitol 3.2 g-0.03-0.14
C: Lamivudine 300 mg + Sorbitol 10.2 g0.06-0.14
D: Lamivudine 300 mg + Sorbitol 13.4 g-0.24-0.14

[back to top]

Change From Baseline in Mean Corpuscular Volume (MCV)

Blood samples were collected at Day -1, Day 3 of every treatment period and at follow-up. Change from Baseline for MCV was calculated as the post-dose visit value minus the value at Baseline, at Day 3 and Follow-up. Baseline value used in the analysis was the latest pre-dose values on Day 1 of each treatment/period. Day -1 presented the Baseline absolute values; Day 3 and Follow-Up presented the changes from Baseline. (NCT02634073)
Timeframe: Baseline and up to 5 weeks

,,,
InterventionFemtoliter (Mean)
Day 3Follow up
A: Lamivudine 300 mg0.71-0.77
B: Lamivudine 300 mg + Sorbitol 3.2 g0.63-0.77
C: Lamivudine 300 mg + Sorbitol 10.2 g0.35-0.77
D: Lamivudine 300 mg + Sorbitol 13.4 g0.44-0.77

[back to top]

Change From Baseline in Platelets, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils

Blood samples were collected at Day -1, Day 3 of every treatment period and at follow-up. Change from Baseline for platelets, neutrophils, lymphocytes, monocytes, eosinophils, basophils were calculated as the post-dose visit value minus the value at Baseline, at Day 3 and Follow-up. Baseline value used in the analysis was the latest pre-dose values on Day 1 of each treatment/period. Day -1 presented the Baseline absolute values; Day 3 and Follow-Up presented the changes from Baseline. (NCT02634073)
Timeframe: Baseline and up to 5 weeks

,,,
Intervention10^9 cells/L (Mean)
Platelets, Day 3Platelets, Follow upNeutrophils, Day 3Neutrophils, Follow upLymphocytes, Day 3Lymphocytes, Follow upMonocytes, Day 3Monocytes, Follow upEosinophils, Day 3Eosinophils, Follow upBasophils, Day 3Basophils, Follow up
A: Lamivudine 300 mg19.22.30.35-0.120.10-0.080.01-0.08-0.03-0.01-0.01-0.01
B: Lamivudine 300 mg + Sorbitol 3.2 g13.92.30.42-0.120.17-0.080.03-0.08-0.02-0.010.00-0.01
C: Lamivudine 300 mg + Sorbitol 10.2 g13.82.30.53-0.120.00-0.08-0.02-0.08-0.04-0.01-0.01-0.01
D: Lamivudine 300 mg + Sorbitol 13.4 g6.12.30.31-0.12-0.03-0.08-0.01-0.08-0.03-0.010.00-0.01

[back to top]

Change From Baseline in Pulse Rate

Change from Baseline for pulse rate was calculated as the post-dose visit value minus the value at Baseline, at Day 3 and Follow-up. Baseline value used in the analysis was the latest pre-dose values on Day 1 of each treatment/period. (NCT02634073)
Timeframe: Baseline and up to 5 weeks

,,,
InterventionBeats/min (Mean)
Day 3; n=15, 16, 16, 16Follow up; n=16, 16, 16, 16
A: Lamivudine 300 mg6.55.8
B: Lamivudine 300 mg + Sorbitol 3.2 g3.95.8
C: Lamivudine 300 mg + Sorbitol 10.2 g6.05.8
D: Lamivudine 300 mg + Sorbitol 13.4 g7.45.8

[back to top]

Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

Change from Baseline for DBP and SBP was calculated as the post-dose visit value minus the value at Baseline, at Day 3 and Follow-up. Baseline value used in the analysis was the latest pre-dose values on Day 1 of each treatment/period. (NCT02634073)
Timeframe: Baseline and up to 5 weeks

,,,
Interventionmillimeter of mercury (mmHg) (Mean)
DBP, Day 3; n=15, 16, 16, 16DBP, Follow up; n=16, 16, 16, 16SBP, Day 3; n=15, 16, 16, 16SBP, Follow up; n=16, 16, 16, 16
A: Lamivudine 300 mg5.14.63.67.4
B: Lamivudine 300 mg + Sorbitol 3.2 g4.54.63.17.4
C: Lamivudine 300 mg + Sorbitol 10.2 g2.14.65.17.4
D: Lamivudine 300 mg + Sorbitol 13.4 g5.64.65.37.4

[back to top]

Number of Participants With Any Adverse Events (AEs) and Any Serious Adverse Events (SAE)

An AE is any untoward medical occurrence, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that at any dose results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect or event that may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition. (NCT02634073)
Timeframe: Up to 5 Weeks

,,,
InterventionParticipants (Number)
AEsSAEs
A: Lamivudine 300 mg10
B: Lamivudine 300 mg + Sorbitol 3.2 g20
C: Lamivudine 300 mg + Sorbitol 10.2 g10
D: Lamivudine 300 mg + Sorbitol 13.4 g10

[back to top]

Number of Participants With Treatment Emergent Laboratory Abnormality Grade

Division of Acquired immune deficiency syndrome (DAIDS) Table AE grades 1, 2, 3, and 4 of laboratory abnormalities were applied and grade were summarized by treatment and day and were listed by participant, treatment, day, and actual date and time. Treatment emergent grades are defined as any new toxicity grades or the worsened grades compared to Baseline grade. Treatment emergent lab abnormality Grade 1 for aspartate aminotransferase and sodium at follow-up visit are summarized. (NCT02634073)
Timeframe: Up to Week 5

,,,
InterventionParticipants (Number)
Aspartate AminotransferaseSodium
A: Lamivudine 300 mg11
B: Lamivudine 300 mg + Sorbitol 3.2 g11
C: Lamivudine 300 mg + Sorbitol 10.2 g11
D: Lamivudine 300 mg + Sorbitol 13.4 g11

[back to top]

Plasma Lamivudine Area Under the Plasma Concentration Time Curve (AUC) From Time Zero to the Last Quantifiable Time Point (AUC[0-t]), AUC From Time Zero Extrapolated to Infinity (AUC[0-inf]) and AUC From Time Zero to 24 Hours (AUC[0-24])

Serial blood sample were collected at Pre-dose; 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 16, 24, 36 and 48 hours post-dose in each treatment period. AUC was determined using the trapezoidal rule. Analysis of variance (ANOVA), considering treatment and period as fixed effects and participant as random effect, was performed using Mixed Linear Models procedure to compare the plasma lamivudine Pharmacokinetic (PK) parameters. (NCT02634073)
Timeframe: Day 1 to Day 3 in each treatment period

,,,
Interventionhour (h)*microgram (mcg)/milliliter (mL) (Geometric Mean)
AUC (0-inf); n=16, 14, 16, 13AUC (0-24) ; n=16, 16, 16, 16AUC (0-t) ; n=16, 16, 16, 16
A: Lamivudine 300 mg13.212.412.9
B: Lamivudine 300 mg + Sorbitol 3.2 g11.39.9610.6
C: Lamivudine 300 mg + Sorbitol 10.2 g8.937.548.21
D: Lamivudine 300 mg + Sorbitol 13.4 g8.606.917.55

[back to top]

Plasma Lamivudine Maximum Observed Concentration (Cmax), Concentration at 24 Hour (h) Post-dose (C24) and Last Measurable Concentration (Ct)

Serial blood sample were collected at Pre-dose; 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 16, 24, 36 and 48 hours post-dose in each treatment period. Time of the last measurable concentration (t) was 48 hours for all participants and all treatments. ANOVA, considering treatment and period as fixed effects and participant as random effect, was performed using Mixed Linear Models procedure to compare the plasma lamivudine PK parameters. (NCT02634073)
Timeframe: Day 1 to Day 3 in each treatment period

,,,
Interventionmcg/mL (Geometric Mean)
C24CtCmax
A: Lamivudine 300 mg0.0360.0133.34
B: Lamivudine 300 mg + Sorbitol 3.2 g0.0360.0172.42
C: Lamivudine 300 mg + Sorbitol 10.2 g0.0410.0191.60
D: Lamivudine 300 mg + Sorbitol 13.4 g0.0390.0181.52

[back to top]

Time to Observed Maximum Lamivudine Plasma Concentration (Tmax), Time of Last Measurable Plasma Concentration (Tlast) and Absorption Lag Time in Plasma (Tlag)

Serial blood sample were collected at Pre-dose; 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 16, 24, 36 and 48 hours post-dose in each treatment period. (NCT02634073)
Timeframe: Day 1 to Day 3 in each treatment period

,,,
InterventionHr (Median)
tmaxtlasttlag
A: Lamivudine 300 mg0.7548.000.000
B: Lamivudine 300 mg + Sorbitol 3.2 g1.00048.000.000
C: Lamivudine 300 mg + Sorbitol 10.2 g1.0048.000.000
D: Lamivudine 300 mg + Sorbitol 13.4 g1.2648.000.000

[back to top]